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Abstract 
ABSTRACT 
Jaana Seikkula 
Factors contributing to frozen embryo transfer outcomes 
– assessment of blastomere multinucleation and luteal phase GnRH agonist in 
relation to reproductive outcome  
University of Turku, Faculty of Medicine, Obstetrics and Gynaecology, Doctoral 
Doctoral Program in Clinical Research, Turku, Finland 
Annales Universitatis Turkuensis, Medica-Odontologica, 2019 
Of all embryo transfers in Finland, approximately half are now performed as 
frozen embryo transfer (FET). The effectiveness of FET is dictated by patient 
characteristics, embryo quality, and implantation environment. The significance 
of one of the embryo quality markers, blastomere multinucleation, and the effects 
of modified FET protocols on pregnancy outcomes, course of pregnancy, and 
health of the newborns are not thoroughly clarified. 
The first part of this thesis focused on blastomere multinucleation in frozen-
thawed embryo cohorts: de novo occurrence, associations to factors known to 
contribute to controlled ovarian hyperstimulation (COH) and pregnancy 
potential. Multinucleation was frequent in embryo cohorts before 
cryopreservation, but de novo multinucleation after thawing neither reached the 
level detected before freezing nor was associated with de novo multinucleation in 
sibling embryos. Young female age and higher ovarian response to COH were 
associated with the occurrence of multinucleation, especially before freezing. 
The pregnancy potential of binucleated (BN) and, notably, multinucleated (MN) 
frozen-thawed embryos seemed to be reduced, but this study demonstrated that 
transfer of BN/MN FET could result in acceptable live birth rate (LBR), healthy 
pregnancies, and newborns.  
In the second part of this thesis, the effect of single dose triptorelin as an 
adjuvant to standard luteal support in natural and artificial cycle FETs was 
assessed in prospective pilot studies. The clinically relevant difference in LBR, 
pointing to the benefit of triptorelin, was statistically insignificant. These results 
underline a need for larger multicenter studies before implementing the use of 
triptorelin in clinical practice of FETs. 
KEYWORDS: In vitro fertilization, intracytoplasmic sperm injection, frozen 
embryo transfer, multinucleation, binucleation, luteal phase, adjuvant therapy, 
gonadotropin releasing hormone agonist, triptorelin 
 
Tiivistelmä 
TIIVISTELMÄ 
Jaana Seikkula 
 
Pakastealkiosiirtojen ennusteeseen vaikuttavat tekijät  
– blastomeerien monitumaisuuden ja luteaalivaiheen GnRH agonistituen vaikutus 
raskausennusteeseen 
 
Turun yliopisto, Lääketieteellinen tiedekunta, Synnytys- ja naistentautioppi, 
Turun kliininen tohtoriohjelma, Turku, Suomi 
Annales Universitatis Turkuensis, Medica-Odontologica, 2019 
Kaikista Suomessa tehdyistä alkionsiirroista noin puolet ovat pakastealkion 
siirtoja (PAS). Monet tekijät, kuten potilaan ominaisuudet, alkion laatu ja 
implantaatioympäristö vaikuttavat PAS:n tuloksellisuuteen. Kuitenkaan kaikkien 
alkio-ominaisuuksien, kuten blastomeerien monitumaisuuden tai PAS:ssa käytet-
tävien hoitomenetelmien vaikutusta raskausennusteeseen, raskauden kulkuun tai 
syntyvien jälkeläisten terveyteen ei tarkkaan tiedetä.  
Tutkimuksessa selvitettiin alkion monitumaisuuden esiintyvyyttä pakastealkio-
kohorteissa, yhteyttä koeputkihedelmöityshoidon aikaisen munasarjastimulaation 
vasteeseen vaikuttaviin tekijöihin sekä monitumaisten (MN) alkioiden raskauden 
todennäköisyyttä ja syntyvien lasten terveyttä. Monitumaisuuden esiintyminen 
alkiokohorteissa ennen alkiopakastusta oli tavallista, mutta sen ei havaittu 
lisääntyvän alkiopakastuksen myötä tai lisäävän yksitumaisten sisaralkioiden 
muuntumista monitumaisiksi. Monitumaisten alkioiden esiintyvyys oli yhtey-
dessä erityisesti naisen nuoreen ikään ja korkeaan munasarjastimulaatio-
vasteeseen. Raskauden todennäköisyys MN PAS:n jälkeen oli alentunut, 
varsinkin blastomeerien sisältäessä enemmän kuin kaksi tumaa. Raskaustulos oli 
kuitenkin hyväksyttävä, eivätkä raskaudenkulku tai vastasyntyneiden terveys 
eronneet yksitumaisista alkioista käynnistyneistä raskauksista.  
Tutkimuksen toisessa osassa tutkittiin kerta-annoksena annetun triptoreliinin 
vaikutusta raskaustulokseen luonnollisen kierron ja hormonaalisesti ohjatun 
PAS:n luteaalivaiheen tukihoidon lisänä. Prospektiivisissa pilottitutkimuksissa 
syntyneiden lasten määrässä havaittiin kliinisesti merkittävä ero triptoreliinia 
käyttävän ryhmän eduksi, mutta ero ei ollut tilastollisesti merkitsevä. Laajemmat 
tutkimukset triptoreliinin vaikutuksesta PAS:n raskaustulokseen ovat tarpeen.  
AVAINSANAT: koeputkihedelmöitys, mikroinjektio hedelmöitys, pakaste-
alkionsiirto, monitumaisuus, luteaalivaihe, adjuvanttihoito, gonadotropiineja 
vapauttava hormoni, triptoreliini  
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1 INTRODUCTION 
Cryopreservation of supernumerary embryos is today an integral component of 
assisted reproductive treatments (ART). Embryo cryopreservation has enabled an 
increase in the number of embryo transfers (ET) per patient and, at the same 
time, a decrease in the number of transferred embryos. Implementation of 
elective single ET (eSET) policy and freezing of supernumerary good-quality 
embryos has significantly reduced multiple pregnancies and improved perinatal 
outcomes in ART (Henningsen et al., 2015). In addition, freezing of all embryos 
derived from in vitro fertilization (IVF) and intracytoplasmic sperm injection 
(ICSI) cycles to perform frozen embryo transfer (FET) later on, is an option to 
minimize the risk for ovarian hyperstimulation syndrome (OHSS) and related 
maternal morbidity (Chen et al., 2012, Henningsen et al., 2015). All in all, 
embryo cryopreservation has promoted the cumulative success rate of IVF and 
ICSI cycles, cost-efficiency of ART, and patient safety. Improved FET results 
have encouraged clinicians to take advantage of more individualized approaches 
in ART to avoid pregnancy and perinatal complications. 
The development of IVF culminated in the first live birth in 1978, and ICSI, 
developed to overcome male infertility, resulted in a live birth in 1991. The first 
live birth after transfer of a frozen-thawed embryo was reported in 1984 (Wang 
et al., 2006, Zeilmaker et al., 1984). However, the success rate for FET has 
remained significantly lower compared to fresh ET until the introduction of 
modern embryo culture and cryopreservation techniques in the first decade of the 
21st century (Abdelhafez et al., 2010, Ferraretti et al., 2017, Rienzi et al., 2017). 
Today, FET provides comparable pregnancy outcome to fresh ET. Along with 
improved results, the proportion of FET cycles to all ART treatments has 
increased in Europe, from 12% to 21% between 1997 and 2011 (Ferraretti et al., 
2017). Also, in Finland, the proportion of FET to all ART treatments have 
increased steadily from the beginning of the 21st century, with simultaneous 
improvement in FET outcomes. Altogether, 3565 FETs were performed in 2016, 
of which 797 resulted in a live birth, representing 1.5% of all deliveries. During 
the preceding 15-year period, live birth rate (LBR) of FET cycles rose from 11% 
to 22%. In 2016, ART treatments using own gametes, 24% of fresh ETs, and 
22% of FETs resulted in live births. Today, half of the ETs are performed as FET 
in Finland (THL, 2018). 
Although modern cryotechniques have closed the gap in pregnancy outcomes 
between ET and FET, failed ART cycles continue to represent a significant 
challenge in daily clinical practice. The probability of ET/FET resulting in 
pregnancy consists of a complex combination of related causes for infertility, 
embryo quality, and endometrial receptivity. Targeted embryo selection aims to 
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reduce the number of unsuccessful treatment cycles. Morphological features of 
an embryo and their true impact on pregnancy potential should be recognized to 
diminish embryo wastage. During the first cleavages, embryos may exhibit more 
than one nucleus within a blastomere, a phenomenon referred to as blastomere 
multinucleation. Multinucleation is one of the embryo quality markers and is 
associated with other embryo features illustrating poor embryo quality 
(Hardarson et al., 2001,  Liu et al., 2014a, Van Royen et al., 2003, Zhan et al., 
2016). Embryos carrying multinucleated (MN) blastomeres have previously been 
discarded from ET because of concerns for the chromosomal health of the 
embryo. Therefore, evidence of pregnancy and neonatal outcomes after MN ET 
are currently scarce. Also, data on multinucleation in frozen-thawed embryos is 
limited (Agerholm et al., 2008, Desai et al., 2016, Egashira et al., 2015). 
Moreover, alternative approaches have been studied along with standard 
endometrial preparation protocol in an attempt to promote endometrial 
receptivity before ET/FET. Before implementing different adjuvant therapies into 
routine practice, safety and efficacy should be promptly analyzed. Gonadotropin 
releasing hormone (GnRH) agonist, combined with standard luteal support in 
fresh ETs, have shown promising results in increasing implantation and LBR, 
particularly in IVF/ICSI cycles stimulated with an antagonist protocol 
(Benmachiche et al., 2017, Isik et al., 2009, Kung et al., 2014, Simsek et al., 
2015, Tesarik et al., 2006, Zafardoust et al., 2015). The quality of data is, 
however, poor and conflicting. The luteal phase in FET cycles differs profoundly 
from stimulated IVF/ICSI cycles, and therefore results from fresh ETs are not 
directly applicable to FET. Data on the effect of additional luteal phase GnRH 
agonist in natural cycle (NC) FETs or artificial cycle (AC) FETs is limited to 
only a few studies (Davar et al., 2015, Orvieto et al., 2016, Ye et al., 2019, Zarei 
et al., 2017). 
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2 REVIEW OF LITERATURE 
2.1 Clinical outcomes of FET 
2.1.1 Pregnancy outcomes 
Embryo cryopreservation was originally designed to reduce the number of 
transferred embryos during fresh ETs and complications related to ART, such as 
OHSS, multiple pregnancies and preterm birth. Nowadays, along with improved 
cryotechniques, preserving supernumerary embryos for later use has become a 
convincing option to increase the cumulative pregnancy rate (PR) of ART, and is 
today perceived as a complementary, or even preferable, procedure to fresh ET 
(Acharya et al., 2018, Tiitinen et al., 2001). Historically, LBR has been higher 
among fresh ETs compared to FET. The discrepancy in outcomes is partly 
explained by the strategy of transferring the best-quality embryos during a fresh 
cycle, while cryopreserved embryos exhibited more compromised quality 
compared to embryos selected for ET. Advanced cryotechniques and a shift in 
practice patterns toward blastocyst culture and more liberal use of 
preimplantation genetic testing for aneuploidies (PGT-A) and freeze all strategy 
have nowadays equalized pregnancy outcomes between fresh ET and FET 
(Evans et al., 2014, Roque et al., 2019). 
According to a large analysis of ART data in Europe, PR per FET increased 
steadily from 14% to 22% between 1997 and 2011, whereas a simultaneous rise 
in PR per fresh ET was from 24% to 28% (Ferraretti et al., 2017). There is 
growing evidence that with current cryotechniques, pregnancy outcomes of 
FET cycles, including clinical pregnancy rate (CPR) and LBR, yield 
comparable results and even better outcomes than fresh ET, especially in 
women with a high response to controlled ovarian hyperstimulation (COH) 
(Acharya et al., 2018; Roque et al., 2019, W. Zhang et al., 2018). Accordingly, 
in Finland, LBR in FET and fresh ET is similar (22.0% and 23.9%, 
respectively) (THL, 2018). 
2.1.2 Neonatal outcomes 
Along with a progressive increase in the use of FET, reassuring safety data 
regarding the impact of cryoprotectants and freezing-thawing methods on the 
health of the newborns have been shown. The impact of cryopreservation 
processes on perinatal and neonatal outcomes have been evaluated in several 
meta-analyses (Berntsen and Pinborg, 2018, Sha et al., 2018, Zhao et al., 2016). 
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According to a Finnish cohort study, a safety profile regarding the risk for 
preterm birth (6.5% vs. 8.8%), low birth weight (4.2% vs. 6.0%), or small for 
gestational age (1.5% vs. 3.1%) seems to be in favor of FET (n = 2,293) 
compared to fresh ET (n = 4,151), whereas course of pregnancy is the most 
favorable in spontaneous pregnancies (n = 31,946) (Pelkonen et al., 2010).  
By contrast, current data on the increased risk of large for gestational age among 
neonates born from FET cycles are convincing (Berntsen and Pinborg, 2018, 
Kato et al., 2012, Pelkonen et al., 2010, Sha et al., 2018). In a meta-analysis of 
more than 100,000 FET singletons, a 1.5-fold risk for large for gestational age 
and a 1.7-fold risk for macrosomia was observed in neonates born from FET 
compared to fresh ET (Berntsen and Pinborg, 2018) Another meta-analysis of 31 
studies showed results consistent with earlier evidence, pointing out a decreased 
risk for low birth weight, preterm birth, and perinatal mortality compared to fresh 
ET, whereas pregnancy-induced hypertension, postpartum hemorrhage, and 
increased birth weight associated with FET (Sha et al., 2018). Interestingly, two 
recent retrospective analyses found increased birth weight to be associated with 
AC-FET rather than NC-FET (Ishii et al., 2018, Tsuji et al., 2017). This finding 
was not, however, supported by another large retrospective analysis of different 
FET protocols, which instead found AC-FET to associate with hypertensive 
disorders during pregnancy and postpartum hemorrhage compared to NC-FET 
(Ginström Ernstad et al., 2019). These results suggest that the preparation of 
endometrium and hormonal milieu may contribute to conditions exposing 
maternal and perinatal complications. 
Congenital anomalies (CAs) are more frequently seen in children born after ART 
compared to natural conception (Berntsen et al., 2019). In a meta-analysis of 
112,913 ART children and 4,471,368 naturally conceived children, the risk for 
CAs was increased 1.4-fold in children born after ART (Zhao et al., 2018). In a 
large Scandinavian cohort, however, the absolute increase in risk for CAs was 
only 0.5% among ART children (Henningsen et al., 2018). The risk for CAs 
seems not to be related to the method of fertilization (IVF or ICSI) but instead, 
the risk for chromosomal abnormalities is reported to be associated with ICSI 
and male infertility compared to IVF (Berntsen et al., 2019). According to the 
available data, the risk for major CAs is not increased among singleton neonates 
born from FET cycles compared with children born after fresh ET (Aflatoonian 
et al., 2010, Kato et al., 2012, Pelkonen et al., 2014, J. Zhang et al., 2018). 
Available data suggest an overall good prognosis in the long-term health of ART 
children, although potential increases in blood pressure and compromised 
metabolic and cardiovascular profiles compared to spontaneously conceived 
children have been reported (Berntsen et al., 2019). No difference was detected 
in physical health in early childhood or academic performance at adolescence 
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between children born from FET or fresh ET cycles (Pelkonen et al., 2015, 
Spangmose et al., 2018).  
The mechanism behind the increased risk for CAs in ART remains unclear. The 
process of IVF/ICSI, including ovarian stimulation, manipulation of the gametes 
and embryo, and embryo exposure to different culture media have been 
suggested as causative factors (Zhao et al., 2018). Some implications on the 
causality between infertility rather than the ART process and risk for CAs have 
been postulated. Sub-fertility has been found to be an independent risk factor for 
CAs as, for example, prolonged time to pregnancy per se is reported to associate 
with increased prevalence of CAs (Davies et al., 2012, Zhu et al., 2006). Another 
explanation involves epigenetic changes in gene imprinting due to the ART 
process. Aberrant DNA methylation may alter gene transcription that impacts 
embryo development negatively (Berntsen et al., 2019, Palermo et al., 2008). 
Further, during blastogenesis, normal interaction in nuclear mechanics and 
cellular organization, function, and movement are needed for subsequent normal 
organogenesis. Defects in blastogenesis commonly affect the formation of the 
midline, of which monozygotic twins represent a rare example. Hypothetically, 
early embryos may carry features like multinucleation, which later affect cell 
migration and exposure to defects in organogenesis (Halliday et al., 2010). 
2.2 Factors contributing to FET results 
Several factors, including clinical features of the infertile couple and the ART 
process, may affect FET outcomes (Figure 1). This paragraph focuses on the 
critical steps of FET treatment that may impact FET outcomes. 
 
Figure 1. Factors affecting frozen embryo transfer outcome. 
FET OUTCOME 
Clinical features of the 
infertile couple 
Cryopreservation 
method 
Endometrial 
preparation for FET 
Adjuvant therapies Embryo selection 
IVF laboratory quality  
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2.2.1 Embryo selection 
Human embryos undergo sequential mitotic divisions of cells in which the entire 
genomic information is replicated and further reproduced by nuclear division (Fritz 
and Speroff, 2005, ESHRE, 2012). Visualization of female and male pronuclei 
within the inseminated oocyte is a sign of normal fertilization. Eventually, these 
two haploid complements of chromosomes merge to form a diploid chromosomal 
constitution and set a base for the first cell division. The first cell cycle, when the 
2-cell embryo is formed, is completed approximately 20-26 hours after fertilization 
and after that, mitotic divisions occur within a time range of 12-16 hours. 
Eventually, the embryo begins compaction at the 8-cell stage, and the cleavage 
stage ends with the formation of morula and embryo enters to blastocyst stage 
generally five days after fertilization (Prados et al., 2012, ESHRE, 2012). 
Normally fertilized oocyte and embryo cleavage patterns are presented in Figure 2. 
The cleavage behavior of embryos cultured in vitro may be affected by the 
disruption of mitosis, leading to various morphological alterations. 
 
Figure 2. Embryo development from normally fertilized oocyte to day-5 blastocyst stage. 
Morphological scoring of preimplantation embryos is a critical step in ART, 
determining embryo selection for fresh ET, cryopreservation, and subsequent 
FET. Sequential embryo screening includes embryo evaluation at specific time 
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points, whereas embryo monitoring with a time-lapse embryoscope allows 
continuous observation of the developmental stages of the embryo in an 
automated incubation system. No clear consensus regarding the superiority of 
these two protocols has been established (Armstrong et al., 2018). In 2011, an 
international consensus by the European Society of Human Reproduction and 
Embryology’s expert panel defined the minimal criteria for embryo assessment. 
In the cleavage stage, the morphologic evaluation of embryos includes the 
evaluation of cell number and symmetry, embryo fragmentation, and blastomere 
nuclearity whereas blastocysts should be assessed by the developmental stage 
and morphology of the inner cell mass and the trophoectoderm (TE) (Alpha and 
ESHRE, 2011). The impact of multinucleation on FET outcome is discussed in 
detail in paragraph 2.3.  
The embryo age at the time of ET or embryo cryopreservation generally varies 
from day-2 embryos to blastocysts. The use of extended embryo culture in FETs 
has increased significantly. In 2013, 70-80% of FETs in the United States were 
blastocyst transfers. A large nationwide cohort study that included more than 
200,000 FETs from the United States noted significantly improved LBR, 
decreased miscarriage rate, and similar perinatal outcomes among blastocyst 
transfers compared to cleavage stage FET (Holden et al., 2017), but no benefit 
was found in cumulative pregnancy outcomes or LBR per FET favoring 
blastocyst transfers in a meta-analysis, as found by Martins et al. (2017). 
Extended embryo culture seems to decrease the time to pregnancy in FET cycles 
by enabling more detailed observation of embryo development and viability. 
However, prolonged exposure to in vitro culture conditions may adversely affect 
the embryo and lead to undesirable epigenetic changes in the offspring. Also, the 
embryo culture to the blastocyst stage seems to be associated with increased risk 
for monozygotic twinning (Berntsen et al., 2019). 
Currently, no uniform worldwide protocol for embryo selection for 
cryopreservation exists, and criteria are subjected to individual IVF laboratory 
policies. Heterogenic protocols challenge the comparison between FET outcomes 
and complicate the evaluation of FET study methods and results. 
2.2.2 Cryotechniques 
The slow freezing technique and ultrarapid vitrification are two principal 
approaches used for embryo cryopreservation. During the freezing process, ice 
crystallization of intracellular water causes cellular damage and impairs 
cryosurvival of the embryos. The cells are dehydrated by a series of 
cryoprotectants with rising concentration to avoid ice crystal formation. 
Relatively low concentrations of cryoprotectants are used in the slow freezing 
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method, and intracellular ice formation is minimized by a controlled slow 
cooling rate. (Fuller and Paynter, 2004, Mazur, 1990). The slow freezing 
protocol was the first cryotechnique adopted in worldwide clinical practice. 
In vitrification, high concentrations of cryoprotectants and ultrarapid cooling are 
used. The ultrarapid cooling rate is achieved by dripping the cryovials directly 
into liquid nitrogen. Instant cooling to –196oC results in glass-like ice without 
crystal formation (Vajta et al., 2015). Vitrification is gradually replacing slow 
freezing as the method of choice for embryo cryopreservation, although concerns 
regarding the impact of high concentrations of cryoprotectants during the 
vitrification process have emerged (Abdelhafez et al., 2010, Berntsen et al., 2019, 
Loutradi et al., 2008). 
Blastomere survival after freezing and thawing predominantly defines the impact 
of cryopreservation on the pregnancy potential of thawed embryos. Fully intact 
embryos after thawing possess equivalent implantation rates (IR) to fresh 
embryos, whereas IR of embryos with 50% cell survival reach only half the rate 
of fully intact embryos (Edgar et al., 2000). Eluding formation of intracellular ice 
crystals is vital for blastomere survival. In this regard, vitrification is a more 
stable cryo-thaw method compared to slow freezing. 
Several studies have demonstrated that vitrification is superior to the slow 
freezing protocol in terms of survival rate and pregnancy outcomes in all 
developmental stages of embryos; LBR was found to be similar or was in favor 
of vitrification compared to slow freezing (Balaban et al., 2008, Kaartinen et 
al., 2016, Z. Li et al., 2014, Peeraer et al., 2015, Rezazadeh Valojerdi et al., 
2009). In a study by Kaartinen et al. (2016), LBR remained comparable, but the 
number of thawed embryos needed to produce a live birth was lower among 
vitrified than slow-frozen embryos (Kaartinen et al., 2016). In a large 
retrospective cohort study of 11,644 slow-frozen blastocyst transfers and 
19,978 vitrified blastocyst transfers, vitrified-thawed cycles were more likely to 
result in FET than slow frozen-thawed cycles, and live birth occurred more 
frequently if the embryo was vitrified (Z. Li et al., 2014). The perinatal 
outcome of neonates seems comparable after vitrification or slow freezing 
(Kaartinen et al., 2016, Z. Li et al., 2014). It is noteworthy that current data on 
neonatal outcomes are predominantly analyzed from FET cycles in which 
cryopreservation was performed using the slow freezing method, although 
reassuring data on the safety of vitrification is accumulating (Berntsen et al., 
2019, Pelkonen et al., 2015, Spangmose et al., 2018). Not all authors agree with 
the ongoing practice of substituting slow freezing of cleavage stage embryos 
for vitrification since equivalent LBR is still achievable with the slow freezing 
protocol (Edgar and Gook, 2012, Zhu et al., 2015). 
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2.2.3 Role of the endometrium 
In the normal ovulatory cycle, the endometrium undergoes stromal cell 
differentiation mediated by cyclic sequential secretions of ovarian steroids, 17β-
estradiol, and progesterone (Duc-Goiran et al., 1999). The regrowth of the 
endometrium is activated when epithelial and stromal cells, the two main cell 
types of the endometrium, begin proliferation as a response to rising estrogen at 
the beginning of the menstrual cycle. Mitotic activity and increased nuclear DNA 
and cytoplasmic RNA synthesis are accelerated preceding the shift from the 
proliferary phase to the preimplantation period of the menstrual cycle (Fritz and 
Speroff, 2005, Piltonen, 2016). 
After ovulation, estrogen-driven endometrial proliferation is inhibited by the rising 
levels of progesterone. These hormonal changes induce secretory transformation 
of the uterine glands, called decidualization of the endometrium, and prepares the 
uterus for pregnancy, irrespective of the presence of a conceptus (Fritz and 
Speroff, 2005, Piltonen, 2016). Microarray studies have found that decidualization 
is a complex cascade of sequential reprogramming of functionally related families 
of genes involved in the extracellular matrix organization, cell adhesion, 
cytoskeletal organization, signal transduction, metabolism, stress responses, cell 
cycle progression, differentiation, and apoptosis (Gellersen et al., 2007). Upon 
implantation, decidua further develops to control the process of placentation.  
The window of implantation (WOI) represents the period of maximal 
endometrial receptivity during which the uterine environment is the most 
favorable for nidation (Karizbodagh et al., 2017). The WOI opens approximately 
6-8 days after ovulation and is maintained for four days. In humans, the time of 
onset and duration of WOI exhibit individual variation, and the mechanisms 
regulating the conversion of endometrium -first into receptive and further into 
refractory phase- are poorly understood (Achache and Revel, 2006, Bergh and 
Navot, 1992, Lessey, 1998, Piltonen, 2016). 
2.2.4 Endometrial preparation in FET 
Synchronization between the endometrial development and the embryo is critical 
for the success of implantation. Preparation of the endometrium for pregnancy 
requires complex cross-talk between autocrine and paracrine factors in the 
maternal environment and between mother and the embryo. The main mediators 
of stromal growth, estrogen and progesterone, also regulate the expression of 
several growth factors and cytokines involved in the endometrial maturation 
process and embryo-endometrial signaling (Karizbodagh et al., 2017). The 
endometrium also responds to several pregnancy-specific proteins secreted by the 
developing blastocyst (Duc-Goiran et al., 1999). 
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In IVF/ICSI treatments, the administration of GnRH agonist or antagonist, as 
well as the development of multiple corpora lutei after controlled ovarian 
hyperstimulation, are known to induce iatrogenic luteal phase defect, which is 
compensated by exogenous progesterone administration. Compared to IVF/ICSI 
cycles, the hormonal milieu differs profoundly in the NC. Proof of the luteal 
phase defect is not as well described in NC-FET, in a modified natural cycle 
(mNC) FET, or the ovulation induction cycle (OI) FET compared to IVF/ICSI. 
However, the use of luteal phase support (LPS) has been adopted in routine 
practice in NC-FET and is also often used in mNC-FET and OI-FET (IVF 
worldwide, 2018, S. Li et al., 2014, Mackens et al., 2017, Yu et al., 2015).  
The main issue in various FET protocols is the creation of an embryo-endometrial 
synchrony corresponding to the conditions that take place during natural conception 
and placentation. This process requires normal endometrial proliferation, the 
transition from the proliferative phase to the secretory phase, optimal timing of FET, 
and an adequate luteal phase. Receptive endometrium can be achieved both during 
natural and hormonally substituted cycles. Different endometrial preparation 
methods and basic principles for selection of FET protocol are presented in Table 1. 
Vaginal micronized progesterone is the most commonly used preparation for 
LPS, whereas oral or intramuscular supplementation of progesterone are optional 
administration routes. In NC-FET, repeated dosages of human chorionic 
gonadotropin (hCG) have been used as an alternative to luteal phase progesterone 
supplementation, although recent data do not support its beneficial effect (Lee et 
al., 2017). In Finland, LPS is routinely continued for two weeks until the 
pregnancy test. In AC-FET, selection of the dominant follicle is suppressed, and 
endometrial proliferation is induced by administration of exogenous estrogen. 
Table 1. FET preparation protocols. 
FET –protocol Principal selection criteria 
Hormonal preparation of endometrium 
in follicular phase 
 
Natural cycle FET 
(NC-FET) 
 
Spontaneous ovulatory 
cycle 
None  
Modified natural cycle 
FET (mNC-FET) 
 
Timing of FET in 
ovulatory cycle  
None  
Ovulation induction 
FET (OI-FET) 
Oligo- or anovulatory 
cycle 
Recombinant FSH, human menopausal 
gonadotropin, or aromatase inhibitor 
 
 
 
Artificial cycle FET 
(AC-FET) 
Oligo- or anovulatory cycle, 
flexible timing of FET 
Oral/vaginal/transdermal estradiol or 
synthetic estrogen  
 
FET: frozen embryo transfer, LH: luteinizing hormone, FSH: follicle stimulating hormone 
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Once sufficient endometrial thickness is achieved, oral, intramuscular, or vaginal 
progesterone is combined with estrogen supplementation to initiate endometrial 
secretory changes (Leonard et al., 2015). Due to the absence of pituitary 
mediated changes in endogenous ovarian steroid production in early pregnancy, 
hormonal replacement therapy (HRT) must be continued until the onset of 
placental steroidogenesis. However, no proven concept for the optimal length of 
luteal support in AC-FET has been established (Mackens et al., 2017). 
Miscarriages and biochemical pregnancies are described to occur more 
frequently in AC-FET cycles. Nonetheless, LBR remains equal compared to 
other FET protocols (Cerrillo et al., 2017, Tomás et al., 2012). All in all, several 
studies show no difference in LBR between different FET protocols (Cerrillo et 
al., 2017, Givens et al., 2009, Groenewoud et al., 2016, S. Li et al., 2014, Peeraer 
et al., 2015, Yu et al., 2015). However, the largest studies involve only the 
comparison of NC-FET and AC-FET, and in some cases, also extend to mNC-
FET. Two meta-analyses verify comparable pregnancy outcomes of these three 
protocols (Groenewoud et al., 2017, Yarali et al., 2016). However, recent data 
give some indication of the beneficial effect of OI with letrozole for endometrial 
preparation compared to NC-FET or AC-FET (S. Li et al., 2014, Tatsumi et al., 
2017). In a meta-analysis by Yarali et al. (2016), OI with letrozole showed a 
promising effect on FET pregnancy outcome, although adequately powered 
randomized controlled trials (RCTs) are currently lacking. 
2.2.5 Adjuvant therapies in assisted reproduction treatments 
A wide range of adjuvant therapies with a variety of different mechanisms of 
action has been used in ART in an attempt to improve ET or FET outcomes. 
 
 Ultrasound parameters Intervention prior  to FET 
Timing of embryo  
transfer 
 Growth of the dominant 
follicle and thickness of 
endometrium 
Urinary LH measurements According to the spontaneous 
ovulation detected from 
urinary LH measurements 
 Growth of the dominant 
follicle and thickness of 
endometrium 
Pharmacological triggering of 
ovulation 
According to the triggered 
ovulation 
 Growth of the dominant 
follicle and thickness of 
endometrium 
With or without 
pharmacological triggering of 
ovulation 
According to the spontaneous 
ovulation detected from urinary 
LH measurements, or according 
to triggered ovulation  
 Thickness of endometrium and 
absence of the dominant follicle 
Initiation of oral/intramuscular/ 
vaginal progesterone  
According to the initiation of 
progesterone treatment 
 
 
22 Review of literature 
These interventions, several of which are experimental, are more often offered to 
women suffering from previous failed IVF/ICSI cycles, repeated miscarriages, or 
severely compromised ovarian function. Adjuvant therapies can be administered 
before embryo transfer, in the luteal phase or during the entire IVF/ICSI or FET 
cycle, although most of the studies predominantly involve fresh ET. Pretreatment 
prior to IVF/ICSI with different types of adjuvant therapies, such as antibiotics, 
dopamine agonists, intravenous immunoglobulins, intrauterine hCG, low-dose 
acetylsalicylic acid, heparin, uterine relaxants, Co-enzyme Q10, melatonin, 
acupuncture, and filgrastim have been used with little or no evidence of their 
positive effect on LBR (Aaleyasin et al., 2015, Gat et al., 2016, Kalampokas et 
al., 2017, Nardo et al., 2015, Polanski et al., 2014, Revelli et al., 2008, Seto et al., 
2017, Shirlow et al., 2017, Ubaldi et al., 2002, Wang et al., 2017, Xu et al., 
2018). Recent meta-analyses of the use of dehydroepiandrosterone or growth 
hormone as a pretreatment prior to IVF/ICSI in women suffering from poor 
ovarian reserve identified possible positive effects on pregnancy outcomes (Li et 
al., 2017; Liu et al., 2018; Pacchiarotti et al., 2016, Zhang et al., 2016). 
Administration of short-acting GnRH agonist as adjuvant therapy for traditional 
LPS has drawn attention and has been adopted widely into clinical practice, 
without solid evidence of its beneficial effect (Martins et al., 2016, Oliveira et al., 
2010, Tesarik, 2018). The role of short-acting GnRH agonist as adjuvant therapy 
in fresh ET and FET is discussed in detail in paragraph 2.4. 
2.3 Blastomere multinucleation, an embryo quality marker  
2.3.1 Definition and classification 
Blastomere multinucleation is a nuclear abnormality detected in the microscopic 
evaluation of the embryo. Normally only a single nucleus per blastomere is 
present, whereas in blastomere multinucleation at least one blastomere of the 
embryo exhibits more than one nucleus. Blastomere multinucleation can be further 
divided into two subgroups according to the number of detected nuclei: the 
binucleated (BN) blastomere carries two nuclei per cell, and the multinucleated 
(MN) blastomere more than two nuclei per cell (Figure 3). MN blastomeres are 
also called micronucleated, as they exhibit several small-sized nuclei. 
Multinucleation can be evaluated only during the early embryonic cell divisions, 
from 2- to 8-cell stage, while each blastomere is individually detectable (ESHRE 
2012; Fritz and Speroff, 2005, Rienzi et al., 2005). Blastomere multinucleation is 
one of the morphologic features recommended to be evaluated in an embryo 
grading protocol (Alpha and ESHRE, 2011, Holte et al., 2007).  
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Figure 3. A. Binucleated embryo B. Multinucleated embryo. 
2.3.2 Formation of multinucleation 
Karyokinesis without cytokinesis, i.e., division of the nucleus without division of 
the cytoplasm, has been proposed as one of the mechanisms leading to the 
formation of multinucleation. This type of cell cycle error could be a main 
contributor especially for the development of BN blastomeres (Hardy et al., 
1993, Pickering et al., 1995). During mitotic cell division, multiple small nuclei 
may arise from the abnormal organization of the mitotic spindle at prophase and 
defective chromosome migration at anaphase. As chromosomes move to opposite 
sides of the cell, lagging chromosomes may form separate micronuclei during the 
following interphase (Munné and Cohen, 1993, Staessen and Van Steirteghem, 
1998, Winston et al., 1991). Furthermore, partial fragmentation of the nuclei may 
also cause blastomere multinucleation (Munné and Cohen, 1993). 
Programmed cell death, called apoptosis, is strongly associated with nuclear 
fragmentation (Delimitreva et al., 2005, He et al., 2009). In 1987, it was 
discovered that MN blastomeres do not possess the typical activation of gene 
expression at the 8-cell stage compared to mononucleated sibling blastomeres. 
The authors debated that this functional inactivation could be a physiological 
action leading to developmental arrest and elimination of the affected 
blastomeres from the embryo (Tesarik et al., 1987). Therefore, certain blastomere 
multinucleation patterns may reflect a stage of apoptosis leading to either total 
developmental arrest or to embryo self-correction, in which non-viable cells are 
eliminated from further development (Desai et al., 2018).  
Blastomere fusion, also called reverse cleavage, is a phenomenon occurring in 
early cleavage stage embryos. Reverse cleavage affects embryo developmental 
potential negatively and coincides with multinucleation (Liu et al., 2014b). 
Freezing and thawing of embryos have been proposed to expose the embryo to 
pronounced blastomere fusion, leading to numerical chromosomal changes. The 
A B 
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fusion of two or several blastomeres after thawing results in MN blastomeres 
carrying ploidy errors (Balakier et al., 2000). Theories of the formation of bi- and 
multinucleation are presented in Figure 4.  
 
Figure 4. Theories of the formation of bi- and multinucleation. 
2.3.3 Incidence of multinucleation in fresh and frozen-thawed embryos and 
embryo cohorts 
Generally, blastomere multinucleation is highly prevalent after the first embryonic 
divisions, whereas it is less likely to persist during further embryo development 
(Balakier et al., 2016, Van Royen et al., 2003). In the earliest studies on the 
incidence of multinucleation, bi- or multinucleation detected in sequential embryo 
screening at day-2 and -3 of embryo culture were included in the reported 
incidence, whereupon the rate of multinucleation reached up to 80% in embryo 
cohorts and 30% of the embryos (De Cássia Savio Figueira et al., 2010, Jackson et 
al., 1998, Van Royen et al., 2003). More recently, the incidence of bi- and 
multinucleation has been more frequently determined in specific embryonic 
developmental stages, showing an incidence of 5.8% to 26.2% in 4-cell stage 
embryos (Egashira et al., 2015, Meriano et al., 2004, Yakin et al., 2005). 
Multinucleation may be a temporary and reversible phenomenon, as some MN 
blastomeres exhibit an ability to restore mononuclearity (Balakier et al., 2016). A 
self-correction from MN to mononucleated has been demonstrated to occur in a 
frequency of up to 74% in 4-cell cleavage stage embryos (Aguilar et al., 2016). 
Multinucleation 
Cell cycle error 
- Karyokinesis without 
cytokinesis  
Blastomere fusion 
Chromosome segregation 
errors 
- Spindle disorganization  
- Defective chromosome 
migration  
Nuclear fragmentation 
Blastomere fusion 
Extrusion of excessive 
chromosomes from the 
blastomere  
Binucleation 
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Given the transient appearance of MN blastomeres within the embryo, the 
incidence of multinucleation may be underestimated by traditional sequential 
embryo screening due to the limited time interval for observation of embryo 
morphology. Continuous imaging of embryo development with an embryoscope 
enables the perception of dynamic morphological changes in the embryo without 
observational time restrictions. During time-lapse imaging, 43% of 2-cell stage 
embryos have been reported to exhibit multinucleation, and the detection rate in 
4-cell stage embryos varies between 15%-25% (Aguilar et al., 2016, Balakier et 
al., 2016, Basile et al., 2014, Desai et al., 2014, Desch et al., 2016). De novo 
appearance of multinucleation, referring to multinucleation not detected in the 
earlier developmental stages of the embryo, has been reported to occur with a 
frequency of 7.5% in 4-cell fresh embryo cohorts and of 6.2% in fresh day-3 
embryos (Aguilar et al., 2016, Van Royen et al., 2003).  
2.3.4 Factors contributing to the formation of multinucleation  
Multinucleation in in vivo fertilized human embryos was demonstrated in 1954, 
indicating that multinucleation is not exclusively an IVF/ICSI related 
phenomenon (Hertig et al., 1954, cited in Tesarik et al., 1987). However, it has 
been debated whether multinucleation may result from hypoxic intrafollicular 
conditions during COH or unfavorable embryo culture conditions (Pickering et 
al., 1990, Van Blerkom et al., 1997, Winston et al., 1991). In 1997, Van Blerkom 
et al. (1997) demonstrated that MN embryos derived predominantly from 
severely hypoxic follicles, and defectively oxygenated follicles were associated 
with an abnormal chromosomal organization within the mature oocytes. High 
levels of estradiol and increased number of retrieved oocytes, a result of an 
exaggerated response to gonadotropins during COH, have been associated with 
multinucleation (De Cássia Savio Figueira et al., 2010, Jackson et al., 1998, Van 
Royen et al., 2003, Yilmaz et al., 2014). However, results are not uniformly 
consistent since in a large cohort of ICSI cycles, the number of retrieved oocytes 
or high estradiol levels did not correlate with the appearance of multinucleation 
(Balakier et al., 2016), and results concerning follicle stimulating hormone (FSH) 
consumption and formation of multinucleation remain controversial (De Cássia 
Savio Figueira et al., 2010, Jackson et al., 1998, Van Royen et al., 2003). 
Female age has an indisputable effect on ovarian response to gonadotropin 
stimulation and pregnancy outcomes in ART. Advanced female age has a strong 
association with an increasing number of chromosomal errors within the oocytes 
and preimplantation embryos. The deterioration in oocyte quality associated with 
increasing female age has been acknowledged to contribute to reduced fecundity 
and poor ART outcomes among aging women. Female age as a predisposing 
factor to blastomere multinucleation has been evaluated with conflicting results. 
26 Review of literature 
Moriwaki et al. (2004) found advanced female age to be associated with the 
formation of MN blastomeres. Later, in a study conducted by Balakier et al. 
(2016), blastomere multinucleation was discovered to be more prevalent among 
women aged over 40 years compared to women less than 35 years old. However, 
not all studies have confirmed these results (Ergin et al., 2014, Meriano et al., 
2004, Van Royen et al., 2003, Yilmaz et al., 2014). As for the role of the male 
partner, no difference in the appearance of multinucleation has been detected 
after fertilization of oocytes with fresh sperm compared to frozen sperm or sperm 
collected from testicular sperm aspiration (De Cássia Savio Figueira et al., 2010). 
The impact of embryo cryopreservation on multinucleation is poorly studied. 
Comparative studies on the frequency of multinucleation between cryo-thawed 
embryos and fresh embryos are lacking, but embryo cryopreservation has been 
postulated to increase blastomere multinucleation due to suboptimal conditions 
during freezing and thawing process (Agerholm et al., 2008). Factors studied 
previously as possible contributors to multinucleation are presented in Figure 5. 
 
Figure 5. Factors studied as a contributors to occurrence of multinucleation. 
Low dose of 
gonadotropins 
during COH 
Fertilization 
method 
Female age 
High no. of 
retrieved 
oocytes 
Accelerated 
response to 
COH 
High levels of 
estrogen during 
COH 
MULTINUCLEATION 
Embryo 
freezing and 
thawing 
Hypoxia during 
multifollicular 
development 
 Review of literature 27 
2.3.5 Developmental capacity of MN embryos 
Blastomere multinucleation appears in concordance with some morphological 
features generally related to diminished embryo developmental potential. 
Multinucleation is associated with increased embryo fragmentation and reverse 
cleavage. Uneven blastomere cleavage coincides with multinucleation as well as 
with low implantation potential and an increased rate of aneuploidy in cleavage 
stage embryos (Hardarson et al., 2001, Liu et al., 2014b, Van Royen et al., 2003, 
Zhan et al., 2016).  
The rate of embryonic development most reliably reflects the overall embryo 
quality (Desai et al., 2016, Shapiro et al., 2001). The ideal cleavage pattern of 
eight cells on day-3 of embryo culture has been reported conjointly with minimal 
incidence of multinucleation (Van Royen et al., 2003). Some reports of reduced 
blastocyst formation among BN/MN embryos have been introduced, especially 
pointing out the detrimental effect of persisting/appearing MN blastomeres after 
the 2-cell stage (Desch et al., 2016, Egashira et al., 2015, Yakin et al., 2005). At 
the 2-cell stage, a developmental arrest occurs with similar frequency among 
mononucleated and BN/MN embryos if normal cytokinesis is displayed at the 
first cleavage. (Hashimoto et al., 2015). Furthermore, the overall comparable 
blastulation rate between mononucleated and BN/MN embryos have been 
reported (Desai et al., 2018).  
Embryo cleavage time until the 4-cell stage is reported to be longer in MN 
embryos compared to their mononuclear counterparts, although the authors 
debated whether this phenomenon indicates active repair mechanisms in MN 
embryos rather than reflects a compromised developmental potential (Balakier et 
al., 2016). This finding is supported by Desch et al. (2017), who reported better 
LBR among MN embryos completing their second mitotic division after a longer 
time. Day-5 and -6 blastocysts derive from BN/MN cleavage stage embryos with 
similar frequency, and therefore the presence of multinucleation seems not to be 
associated with delayed blastulation (Balakier et al., 2016, Desai et al., 2016, 
Staessen and Van Steirteghem, 1998). Development to the blastocyst stage is 
reported to occur more frequently among BN than MN embryos (Meriano et al., 
2004). 
2.3.6 Developmental capacity of sibling embryos 
In 2004, a difference in the pregnancy potential of mononucleated embryos from 
cycles containing either BN or MN sibling embryos was reported; 
multinucleation in an embryo cohort seemed to reduce the pregnancy potential of 
non-MN embryos, in opposition to BN embryos, whose presence did not 
decrease the odds for pregnancy among mononucleated sibling embryos 
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(Meriano et al., 2004). In contrast, later studies revealed that implantation, CPR, 
and LBR of mononucleated sibling embryos compared to embryos deriving from 
non-multinucleated cycles appear to be comparable, although a pronounced 
tendency to early miscarriage among cycles in which MN embryos were present 
but not transferred has been reported. (Egashira et al., 2015, Jackson et al., 1998, 
Yilmaz et al., 2014) Further, blastocyst formation of mononucleated embryos 
derived from cycles containing MN sibling embryos seems to be comparable to 
their counterparts from cycles exhibiting exclusively mononucleated embryos 
(Egashira et al., 2015). 
2.3.7 Chromosomal complement of MN embryos 
Since multinucleation interferes with the nuclear integrity of the blastomeres, 
questions on its relation with an increased incidence of chromosomal 
abnormalities have been asked. In general, aneuploidy at the time of 
conception and during preimplantation development is a very common 
phenomenon and is known to increase along with advanced maternal age. 
Chromosomal abnormalities in a fertilized oocyte originate primarily from 
female meiotic errors. Mitotic erros, instead, contribute to chromosomal erros 
like mosaicism detected at the cleavage stage. The rate of chromosomal 
abnormalities significantly decreases in the blastocyst stage, although the 
overall incidence remains as high as 60%. The difference in aneuploidy rates 
between women of younger and older age ranges also persists in the blastocyst 
stage. The decline in the aneuploidy rate is likely attributable to the 
developmental arrest before transitioning to the blastocyst stage and the self-
correction methods modulated by the activated gene expression at the cleavage 
stage (Barbash-Hazan et al., 2009, Fragouli et al., 2013, Franasiak et al., 2014, 
Munné et al., 2005).  
Complex aneuploidy at the cleavage stage is commonly accompanied by 
mosaicism (Gutiérrez-Mateo et al., 2011). Whether the embryo is destined to 
arrest or to form a blastocyst is suggested to depend on the type of aneuploidy, 
the way the embryo responds to aberrant gene expression, and whether the 
embryo and its blastomeres possess the ability to restore normal ploidy (Fragouli 
et al., 2013). However, it remains to be answered whether multinucleation 
illustrates blastomere aneuploidy or, instead, active self-correction mechanisms 
to eliminate the excessive chromosomal content of the blastomere. 
The first studies evaluating the chromosomal constitution of cleavage stage MN 
embryos by the fluorescence in situ hybridization (FISH) technique were 
published in the 1990s, demonstrating that some of the MN blastomeres carried 
normal chromosomal complement, and that chromosomal content of the sibling 
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blastomeres did not necessarily correspond to that of BN or MN (Munné et al., 
1994, Munné and Cohen, 1993, Staessen and Van Steirteghem, 1998). The 
chromosomal constitution was aneuploid in 80% of BN/MN embryos having all 
their blastomeres biopsied for FISH analysis on day-4 of embryo development. 
Of those embryos, half had a complex aneuploidy or mosaicism, whereas the 
other half had a combination of normal and abnormal nuclei (Kligman et al., 
1996). In a more detailed analysis, in 3- to 8-cell embryos displaying bi- or 
multinucleation in both blastomeres at 2-cell stage, the chromosomal constitution 
was found to correspond to normal mononuclear diploid status in 30% of cases, 
whereas 34% presented non-diploid constitution indicative of chaotic division. 
Interestingly, 36% had a combination of mononuclear diploid and non-diploid 
blastomeres, suggesting that at least one of the initial BN/MN blastomeres 
possessed normal ploidy or ability to self-correction (Staessen and Van 
Steirteghem, 1998). In a FISH analysis including exclusively MN blastomeres, 
the majority of them were found to be BN after spreading. The rate for uniformly 
diploid nuclei varied between 22% and 50%. (Xanthopoulou et al., 2011, Yilmaz 
et al., 2014) The remaining nuclei consisted of the aneuploid, polypoid, or 
chaotic chromosomal complement. In 64% of BN/MN blastomeres containing 
aneuploid nuclei, genetic content was not identical, indicating unequal 
segregation of chromosomes into multiple nuclei (Yilmaz et al., 2014). 
Aneuploidy records gained from blastocyst stage laser-assisted TE biopsies have 
revealed comparable aneuploidy rates between mononucleated and MN embryos. 
Among MN embryos, all 24 chromosomes contribute to blastocyst aneuploidy. 
Dominant chromosomal abnormalities included single or dual chromosomal 
trisomy, or monosomy of entire or segmental chromosomes (Balakier et al., 
2016).  
In a large cohort of embryos followed with time-lapse imaging and PGT-A, the 
incidence of MN decreased as the embryo cleaved from the 2- to 4-cell stage. 
The majority of the MN 2–cell stage developed into good-quality blastocysts, 
and during early cleavage, correction to mononuclear blastomeres occurred in 
50% of MN embryos, regardless of the ploidy status. Half of the blastocysts 
exhibiting MN blastomeres at the cleavage stage carried a normal chromosomal 
constitution (Balakier et al., 2016), which is comparable to the overall 
aneuploidy rate (Fragouli et al., 2013). In concordance, in an analysis of 26 
blastocysts tested using microarray-based comparative genomic hybridization to 
assess ploidy, half of the blastocysts developed from embryos exhibiting MN in 
both blastomeres at the 2–cell stage (n=9) were euploid (Hashimoto et al., 2015). 
Interestingly, despite the associations reported between multinucleation and 
developmentally detrimental features, no strict correlation between 
morphological features of the embryo and ploidy status has been established. 
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Furthermore, chromosomal abnormalities are present in MN embryos regardless 
of the overall embryo morphology (Balakier et al., 2016, Kligman et al., 1996, 
Staessen and Van Steirteghem, 1998). 
In conclusion, a high aneuploidy rate among BN/MN embryos detected in the 
earliest studies may be related to the timing of analysis, as only cleavage stage 
embryos were examined. Therefore, analysis during cleavage stage may lead to 
overestimation of the number of chromosomal aberrations while possible self-
correction procedures might take place. Recently, more advanced genetic testing 
techniques with TE biopsies from blastocysts have revealed normally developing 
MN/BN embryos to carry normal ploidy status with similar frequency to 
mononuclear blastocysts, questioning the prevalent practice of excluding BN/MN 
embryos from ET. 
2.3.8 Clinical outcomes of MN embryos 
Implantation potential 
Until recently, due to its assumed detrimental effect on pregnancy potential, the 
presence of MN/BN in embryos per se was regarded as a contraindication for ET 
selection. The first reports on pregnancy outcomes of BN/MN embryos in fresh 
ETs included several confounding factors, such as both BN/MN and 
mononucleated embryos, and up to six embryos were transferred simultaneously. 
However, a distinct and consistent reduction in IR compared to mononucleated 
counterparts was observed in early published data (De Cássia Savio Figueira et 
al., 2010, Jackson et al., 1998, Pelinck et al., 1998, Van Royen et al., 2003).  
However, more recent data on the embryo cohorts followed with time-lapse 
imaging revealed a relatively high IR of 18%-28% in cleavage stage embryos, 
and up to 32% in blastocysts deriving from MN 2-cell embryos. According to the 
majority of the studies, IR is at the lowest if both blastomeres are affected at the 
2-cell stage. IR for PGT-A tested euploid MN embryos remained comparable to 
overall IR among MN embryos. In most of the studies a significant difference in 
IR favoring mononucleated embryos was consistent in every subgroup, but also 
comparable IR has been reported regardless of the nuclear status (Aquilar et al., 
2016, Balakier et al., 2016, Desch et al., 2016, Hashimoto et al., 2015). The 
effect of multinucleation on implantation potential seems to be more detrimental 
if the phenomenon persists or appears at the 4-cell stage (Aguilar et al., 2016).  
Birth potential 
Due to the general practice of discarding BN/MN embryos from ET, the earliest 
studies on the clinical relevance of multinucleation included only reports on the 
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development of BN/MN cleavage stage embryos but no data on the pregnancy 
potential. Only the most recent publications have accumulated data on the LBR 
of BN/MN embryos. In the cleavage stage, LBR for fresh embryos exhibiting 
multinucleation at the 2-cell stage has been reported to be significantly reduced 
compared to embryos displaying normal nuclear status. The negative impact was 
most prominent if MN was detected in both blastomeres (Desch et al., 2016). The 
pregnancy potential of MN embryos seems to increase along with normal embryo 
development. Egashira et al. (2015) demonstrated a reduction in LBR in fresh 
cleavage stage MN ETs, whereas LBR was comparable in FETs between MN 
and non-MN blastocysts if an MN embryo had blastulated normally. However, 
reports of less optimistic results postulated that vitrified-warmed blastocysts 
exhibiting multinucleation at the early stages of embryo development were half 
as likely to implant (Hur et al., 2018) or to produce a live birth (Desai et al., 
2016) compared to their mononucleated counterparts. 
Although the number of deliveries from either fresh or frozen-thawed MN ETs 
remains considerably low, growing evidence indicates that blastocysts displaying 
MN at the cleavage stage can produce live births at a relatively high rate. In a 
cohort of 61 blastocysts exhibiting multinucleation at the 2-cell stage, live birth or 
ongoing pregnancy was reported in 41% of fresh ET cycles. If chromosomal 
abnormalities were excluded with PGT-A, the corresponding percentage was as 
high as 64% (Balakier et al., 2016). The tendency to pregnancy loss in embryos 
exhibiting multinucleation at the 2-cell stage relates to the cleavage pattern of the 
embryos; the miscarriage rate is higher among embryos reaching the 4-cell stage 
with shorter cleavage time, less than 37 hours after fertilization (Desch et al., 2016).  
Neonatal outcomes 
Current data on pregnancy complications or neonatal outcomes after transfer of 
BN/MN embryos are limited to small patient series and sporadic reports. Two 
cases of termination of pregnancy due to trisomy 18 and a combination of 
trisomy 21 and 18 after the transfer of an MN embryo have been reported 
(Balakier et al., 2016, Balakier and Cadesky, 1997). Later, a case report of 
conjoined twins (CT) after the transfer of an MN embryo was published 
(Serapinas et al., 2016). Pregnancy was terminated in the second trimester. In 
full-term pregnancies, the number of reported deliveries varied from 1 to 14, 
and all born babies were healthy (Balakier et al., 2016, Balakier and Cadesky, 
1997, Egashira et al., 2015, Hashimoto et al., 2015, Jackson et al., 1998, 
Yilmaz et al., 2014). To date, in the largest cohort of 61 fresh ET transfers 
derived from MN 2-cell embryos, 14 deliveries were documented. No obvious 
difference in neonatal outcomes was observed (Balakier et al., 2016). Neonatal 
outcomes from frozen-thawed BN/MN embryo transfer have been described in 
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only one study; Egashira et al. (2015) reported delivery of 9 healthy newborns 
from transfers of 22 MN embryos.  
Multinucleation and placental development  
Little is known about placental development in pregnancies originating from 
BN/MN embryos. A rare vascular abnormality of the placenta, placental 
mesenchymal dysplasia (PMD), has been related to the binucleation of cleavage 
embryos (Xanthopoulou et al., 2011). Histologically, PMD is characterized 
with enlarged edematous stem villi with dilated vessels and absent trophoblastic 
proliferation. Clinically, PMD is illustrated by placentomegaly and obstetrical 
complications, such as intrauterine growth restriction and fetal demise 
(Kinoshita et al., 2007). PMD is suggested to arise from abnormal fertilization 
or maternal disjunction during the first meiotic division (Kinoshita et al., 2007, 
Pawoo and Heller, 2014). However, an alternative explanation for the 
development of diploid cells of androgenic origin distinctive for PMD is 
karyokinesis of paternal haploid mononucleated blastomere without 
cytokinesis, and therefore, eventually diploid unipaternal cell lineage is formed 
(Xanthopoulou et al., 2011). 
2.4 Short-acting GnRH agonist as adjuvant luteal support  
2.4.1 GnRH function  
GnRH, a decapeptide secreted from the hypothalamus in a pulsatile manner into 
the portal circulation of the hypophysis and then transported to the anterior 
pituitary gland, modulates the mammalian reproduction system by stimulating 
synthesis and secretion of gonadotropins LH and FSH. Two types of GnRH 
receptors are demonstrated to be expressed in multiple extra-pituitary 
mammalian tissues and cells, indicating that the effect of GnRH is not limited 
only to the secretion of pituitary gonadotropins. GnRH receptors are present in 
reproductive organs, such as the placenta, endometrium, myometrium, and ovary, 
and in peri-implantation embryos of different species. This finding has led to 
speculations on a potential role of GnRH as a direct regulator of endometrial 
cells and embryo-endometrial interaction (Casañ et al., 1999, Cheng and Leung, 
2005, Maggi et al., 2016, Metallinou et al., 2007).  
2.4.2 Pharmacokinetics of GnRH agonist 
GnRH agonist is a synthetic decapeptide and agonist analogue of GnRH. GnRH 
agonist has a biphasic effect on pituitary function. Short-term use increases the 
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number of GnRH receptors and provokes synthesis and release of pituitary 
gonadotropins, a phenomenon also called a flare effect. If exposure to GnRH 
agonist continues for a prolonged period, the stimulatory effect of endogenous 
GnRH is inhibited by extended occupation and loss of GnRH receptors. As 
desensitization of the targeted pituitary cells occurs, pituitary gonadotropin 
secretory response is downregulated. In turn, in females, estrogen levels decrease 
to menopausal levels (Cheng and Leung, 2005, Maggi et al., 2016, Pharmaca 
Fennica, 2018). GnRH agonist is available as a long-acting depot and short-acting 
daily formulations. As adjuvant support in the luteal phase of ART cycles, only a 
short-acting GnRH agonist, namely triptorelin, has been investigated (Table 2).  
Triptorelin 
Short-acting triptorelin acetate (Gonapeptyl) contains non-natural amino acid 
substituents, and therefore its duration of action is longer, and its affinity to bind 
to GnRH receptors is higher compared to endogenous GnRH. In a rat pituitary 
cell receptor assay, the receptor affinity of triptorelin was up to 100-fold greater 
compared to natural GnRH. The systemic bioavailability of triptorelin is 
estimated to be nearly 100%. The elimination half-life is three to five hours, and 
the total clearance of triptorelin occurs within 24 hours. In the liver and the 
kidneys, triptorelin is degraded to peptides and amino acids and thereafter 
eliminated renally (Triptorelin, 2015, Pharmaca Fennica, 2018). 
2.4.3 Mechanism facilitating implantation 
Data on the short-acting GnRH agonist supplementation as an additional LPS for 
progesterone supplementation has been accumulating for more than a decade. 
Originally GnRH agonists were investigated as a potential contraceptive and 
abortive agents but were proven to fail as inducers of early pregnancy loss 
(Skarin et al., 1982). In fact, case reports of sporadic spontaneous pregnancies 
under the influence of luteal phase GnRH agonist administration were reported, 
drawing attention toward possible mechanisms enhancing embryo implantation 
(Elefant et al., 1995, Gartner et al., 1997, Tesarik et al., 2004). More recently, the 
concept of GnRH agonist as additional luteal support to traditional LPS was 
extended to the sole use of repeated dosages of GnRH agonist in the luteal phase 
of IVF/ICSI. GnRH agonist as only LPS yielded in comparable results compared 
to progesterone in a pilot prospective randomized comparative study, and this 
result was later strengthened in a large retrospective analysis in which IR and 
LBR were higher in the GnRH agonist group (Bar Hava et al., 2017, Pirard et al., 
2015). Theories of different mechanism of GnRH agonist postulated to enhance 
reproductive function are presented in Figure 6.  
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Table 2. Previous studies on the effect of the gonadotropin releasing hormone agonist 
(GnRHa) administered on the day six (d6) of the luteal phase of IVF/ICSI and FET cycles. 
Author, year, 
and country 
Study  
design 
N:o of transferred embryos Implantation rate  Clinical pregnancy rate   
mean (range or [SD]) % %  
GnRHa d 6 Control GnRHa d6 Control p-value GnRHa d6 Control p-value  
IVF/ICSI stimulation with agonist protocol  
Fujii et al. 2001, 
Japan56 RCT  2.1 (0.1) 2.0 (0.1) 28.5  19.6  <0.05 44.5 (65/146) 34.3 (47/137) <0.05 
 
 
Tesarik et al 
2006, Spain159 RCT 2.3 (0.5) 2.3 (0.5) 29.8 18.2 <0.05 51.1 (72/141)  41.5 (59/142) NS 
 
 
Ata et al 2008, 
Turkey14 RCT 2.65 (2.58-2.72)
b 2.51 (2.42-2.60)b 21.1 20.1 NS 42.8 (122/285) 42.1 (120/285) NS 
 
 
Razieh et al 
2009, Taiwan137 RCT 2.3 (0.8) 2.4 (0.8) 12.3 7.3 0.04 25.6 (23/90) 10.0 (9/90) 0.015 
 
 
Yldiz et al 
2014, Turkey181 RCT 2.71 (0.7) 2.68 (0.7) 20.7 1.3 NS 40.0 (40/100) 31.6 (30/95) NS 
 
 
Inamdar et al 
2012, India71 RCT  2.4 (2.31-2.53)
b 2.54 (2.44-2.64)b 17.6 17.1 NS NA NA  
 
Kung et al 
2014, Taiwan94 
Retrospective 
cohort NA NA NA NA 
 48.1 (37/77) 37.5 (21/56) NS 
 
Simsek et al 
2015, Turkey152 
Retrospective 
cohort 3 (1-6) 3 (1-5) NA NA 
 NA NA  
 
Aboulghar et al. 
2015, Egypt3 RCT  2.6 ± 0.6 2.7 ± 0.6 NA NA 
 36.2 (81/224) 30.6 (68/222) NS 
 
IVF/ICSI stimulation with antagonist protocol  
Isik et al 2009, 
Turkey82 
RCT  
cross-over 2.3 (1.2) 2.2 (1.2) 26.5 9.3 <0.0001 40.5 (30/74) 20.0 (16/80) 0.0055 
 
 
Zafardoust et al 
2015, Iran183 RCT 3.2 (0.9) 2.9 (1.02) NA NA 
 14.0 (6/43) 7.5 (3/40) NS 
 
Tesarik et al 
2006, Spain159 RCT 2.2 (0.4) 2.3 (0.5) 27.1 17.4 >0.05 47.6 (69/145) 37.5 (54/144) NS 
 
 
Kung et al 
2014, Taiwan94 
Retrospective 
cohort NA NA NA NA 
 50.0 (35/70) 27.0 (10/37) 0.025 
 
Check et al 2015, 
United States31 
Prospective 
cohort 1.9 2.0 37.9 33.1 NS 51.5 (69/134) 49.2 (97/197) NS 
 
 
Simsek et al 
2015, Turkey152 
Retrospective 
cohort 2 (1-5) 1 (1-5) NA NA 
 NA NA  
 
Benmachiche et al 
2017, Denmark23 RCT 2.3 (0.5) 2.4 (0.8) 27.3 23.8 NS 38.2 (63/165) 30.9 (51/165) NS 
 
 
Natural cycle FET  
Orvieto et al. 
2016, Israel122 
Retrospective 
cohort 1.8 (0.5) 1.8 (0.5) 31.1 17.3 <0.012 50.8 (30/59) 25.7 (19/74) 0.002 
 
 
Artificial cycle FET  
Davar et al. 
2015, Iran35 RCT 2.4 (0.62) 2.5 (0.63) 14.7 13.1 NS 26 21 NS 
 
 
Ye et al. 2019, 
China179 RCT 2.0 (0.1) 2.0 (0.1) 41.0 39.2 NS 57.7 (246/426) 58.7 (212/361) NS 
 
 
aLBR per transferred embryo, bmean (95% CI), cof positive pregnancy test 
FET= frozen embryo transfer, hCG= human chorionic gonadotrophin, ICSI= intracytoplasmic sperm injection, IVF= in vitro 
fertilization, NA= not available, NS= not significant, RCT= randomized contrrolled trial 
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 Ongoing or live birth rate  Miscarriage rate  
Notification 
 
 % %  
 GnRHa d6 Control p-value GnRHa d6 Control p-value  
 IVF/ICSI stimulation with agonist protocol  
 23.6 (73/309)a 15.7 (44/280)a <0.05 15.4 (10/65) 27.7 (13/47) NS Daily administration of 600 µg buserelin until pregnancy test 
 
 46.8 (66/141)  38.0 (54/142)  NS NA NA   0.1 mg triptorelin   
 31.2 (89/285) 29.5 (84/285) NS NA NA  0.1 mg triptorelin   
 NA NA  NA NA  0.1 mg triptorelin   
 36.0 (36/100) 27.4 (26/95) NS 4.0 (4/100) 4.2 (4/95) NS 1 mg leuprolide   
 27.7 (59/213) 26.3 (56/213) NS 24.3 30.7 NS Three repeated dosages of 1 mg leuprolide   
 40.3 (31/77) 32.1 (18/56) NS NA NA  Cause for administration of 0.1 mg triptorelin not available 
 
 40.8 (469/1149) 41.2 (230/558) NS 16.8 (193/1149) 10.9 (61/558) 0.001 Up to six embryos transferred at ET. Cause for administration of 0.1 mg triptorelin not available 
 
 30.4 (68/224) 25.7 (57/222) NS NA NA  Daily 0.1 mg triptorelin until pregnancy test   
 IVF/ICSI stimulation with antagonist protocol  
 35.1 (26/74) 16.3 (13/80) 0.007 NA NA  Cross-over study, combination of 0.5 mg leuprolide and hCG 
 
 NA NA  NA NA  0.1 mg triptorelin   
 44.8 (65/145) 31.9 (46/144)  <0.05 NA NA  0.1 mg triptorelin   
 42.9 (30/70) 21.6 (8/37) 0.035 NA NA  Cause for administration of 0.1 mg triptorelin not available 
 
 47.8 (64/134) 38.6 (76/197) NS NA NA  1 mg leuprolide administered according to the patient's preference 
 
 32.8 (230/701) 34.4 (114/331) NS 12.1 (85/701)  14.5 (48/331) NS 0.1 mg triptorelin   
 36.4 (60/165) 30.7 (50/163) NS 17.1 (13/76)c 27.5 (19/69)c NS 0.1 mg triptorelin   
 Natural cycle FET  
 45.8 (27/59) 20.3 (15/74) <0.001 NA NA  Intervention and control group from two consecutive time periods, combination of 0.1 mg triptorelin and hCG  
 Articifial cycle FET  
 NA NA 
 
5 8 NS 0.1 mg triptorelin and repeated dosages of acetylsalicylic acid 
 
 46.7 (199/426) 49.3 (178/361) NS 11.0 (27/246) 9.9 (21/212) NS 0.1 mg triptorelin   
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Figure 6. Theories of GnRH agonist action on reproductive function. 
GnRH agonist in embryo-endometrial interaction 
The expression of GnRH and its receptors is up-regulated in mouse embryo after 
the early blastocyst stage and in pregnant mouse uteri. Treatment with GnRH 
agonist has been shown to promote blastocyst development and inhibit apoptosis 
under in vitro culture conditions. Also, GnRH agonist antagonized the apoptotic 
effect of GnRH antagonist on blastocyst development. In all, these findings 
suggested that GnRH acts as an important growth factor in preimplantation 
mouse embryos. (Kawamura et al., 2005). Similarly, GnRH agonist added to the 
culture medium enhanced in vitro blastocyst formation of porcine embryos in a 
dose-dependent fashion, whereas the embryotrophic effect was reversed by 
supplementation of GnRH antagonist (Nam et al., 2005).  
In human in vitro models, the results of the beneficial effect of GnRH agonist on 
embryo-endometrial interaction are inconsistent. In 1999 the presence of both 
GnRH and GnRH receptor in human blastocysts was demonstrated for the first 
time (Casañ et al., 1999). In a study by Klemmt et al. (2009), the in vitro 
decidualization capacity of human endometrial stromal cells or the level of hCG 
secreted by the implanting blastocysts were not affected by the presence of 
GnRH agonist administered in the culture medium. By contrast, Wu et al. (2015) 
demonstrated that GnRH agonist activated cell invasion, migration, and motility 
of human decidual endometrial stromal cells, suggesting an active role in the 
regulation of embryo-endometrial interactions. The difference in study protocols 
may explain this discrepancy; in a study by Klemmt et al. (2009), an endometrial 
sample was collected from non-pregnant uteri during the assumed WOI, whereas 
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Wu et al. (2015) investigated decidual tissue from women undergoing elective 
pregnancy termination in the 6th-12th weeks of gestation.  
In vivo and in vitro β-hCG production has been demonstrated to be stimulated in 
the human placenta by GnRH agonist (Barnea et al., 1991, Siler-Khodr et al., 
1997). Therefore, in clinical studies, β-hCG levels have been interpreted as a 
marker of a potential positive effect of GnRH agonist on early pregnancy 
development in IVF/ICSI cycles. Higher levels of β-hCG and increased LBR 
after administration of mid-luteal GnRH agonist in IVF/ICSI cycles were first 
reported by Tesarik et al. (2006). Furthermore, a retrospective analysis of an 
IVF/ICSI cohort with repeated GnRH agonist as sole luteal support revealed 
higher β-hCG levels among women older than 35 years compared to traditional 
progesterone support (Bar Hava et al., 2017). However, another study (Check et 
al., 2015) reported no difference in the β-hCG production in a non-randomized 
prospective study.  
GnRH agonist and corpus luteum function 
In addition to a possible direct effect on the endometrial receptivity and early 
embryo, mid-luteal GnRH agonist supplementation may facilitate corpus luteum 
function by increasing luteinizing hormone levels and thus prevent luteolysis. 
Luteal phase deficiency is evident in IVF/ICSI cycles, whereas in FET cycles, 
the endometrial milieu is either under normal cyclic hormonal regulation or 
endometrial receptivity is being controlled by exogenous hormonal substitution. 
A stimulatory effect of GnRH agonist on corpus luteum in antagonist IVF/ICSI 
cycles is supported by the finding of increased levels of luteal phase progesterone 
and estradiol in cycles in which single dose GnRH agonist additional to 
progesterone or repeated dosages of GnRH agonist only were used (Bar Hava et 
al., 2017, Benmachiche et al., 2017). Interestingly, this effect was not evident in 
IVF/ICSI cycles stimulated with agonist protocol (Razieh et al., 2009, Fujii et al., 
2001). Understandably no difference in steroid production was noted in 
hormonally substituted oocyte donation recipients due to the absence of corpus 
luteum (Tesarik et al., 2004).  
Clinical studies demonstrate either a neutral or a stimulatory effect of luteal 
phase GnRH agonist on steroidogenesis in IVF/ICSI cycles. These findings 
conflict with in vitro studies in the human ovary, reporting that endogenous 
GnRH acts as a luteolytic factor in luteinized granulosa cells and thus decreases 
progesterone production. Treatments with GnRH agonist has been postulated to 
mimic the effect of endogenous GnRH, although results are not consistent 
(Metallinou et al., 2007). 
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2.4.4 Pregnancy outcomes  
A summary of the study outcomes of luteal phase GnRH agonist in IVF/ICSI, 
NC- and AC-FET cycles are presented in Table 2. 
Fresh embryo transfer 
The first prospective controlled trial in 2004 demonstrated that IR and LBR after 
fresh ET in donated oocyte recipients under HRT were higher if a single dose of 
triptorelin was additionally administered in the luteal phase (Tesarik et al., 2004). 
Few studies have been conducted with findings of the positive effect of 
additional luteal phase GnRH agonist in IVF/ICSI, both in GnRH agonist and 
antagonist cycles (Razieh et al., 2009, Isik et al., 2009, Kung et al., 2014). 
The use of GnRH agonist as adjuvant luteal support seems to increase IR in 
IVF/ICSI cycles when using the agonist protocol. Two RCTs reported a differ-
rence in IR, favoring a mid-luteal single dose GnRHa agonist; Razieh et al. 
(2009) reported an increased CPR, and Tesarik et al. (2006) found an increased 
LBR per transferred embryo. Better IR, CPR, and LBR per transferred embryo 
were reported in an RCT in which repeated dosages of GnRH agonist were used 
in the luteal phase (Fujii et al., 2001). In two RCTs a clinically relevant, although 
statistically insignificant, difference in CPR and LBR favoring GnRH agonist use 
was observed (Aboulghar et al., 2015, Yıldız et al., 2014). In contrast, the largest 
RCT so far published failed to demonstrate a difference between traditional 
progesterone supplementation and additional single dose GnRH agonist in terms 
of ongoing pregnancy (Ata et al., 2008). 
In IVF/ICSI cycles stimulated with antagonist protocol, three RCTs have shown 
an increase of IR if additional GnRH agonist was used. (Isik et al., 2009, Tesarik 
et al., 2006, Zafardoust et al., 2015). However, in an RCT by Benmachiche et al. 
(2017), no difference in IR was demonstrated. Most of those RCTs were 
underpowered to reveal statistical significance in CPR, although a clinically 
relevant difference was systematically noted (Benmachiche et al., 2017, Tesarik 
et al., 2006, Zafardoust et al., 2015). LBR was found to be increased in an RCT 
by Tesarik et al. (2006), both CPR and LBR were higher in GnRH agonist added 
cycles compared to traditional progesterone supplementation in RCT by Isik et 
al. (2009). In a retrospective analysis by Kung et al. (2014) CPR and LBR were 
higher in IVF/ICSI cycles stimulated with antagonist protocol when additional 
luteal phase GnRH agonist was administered, whereas in cycles stimulated with 
agonist protocol, no difference was observed. Notably, the effect of mid-luteal 
GnRH supplementation in antagonist IVF/ICSI cycles was most prominent in a 
subgroup of women with higher basal FSH and lower number of mature oocytes.  
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Natural cycle FET 
The effect of a single dose GnRH agonist on pregnancy outcomes in NC-FET has 
been evaluated in only one retrospective study in which the outcomes of two 
different NC-FET LPS protocols from consecutive periods were compared. 
During the first period, 74 women used progesterone for luteal support, whereas 
during the second period, a modified luteal support protocol with two additional 
injections, hCG and GnRH agonist on the day of transfer and four days later, 
were administered in 46 women. Improvement in IR and ongoing PR were 
observed in the group using a modified luteal support protocol (Haas et al., 
2015). Later, the same research group extended their study to include pregnancy 
outcomes of AC-FETs from the corresponding periods in the analysis. In this 
analysis, the 59 women using modified NC-FET LPS protocol were included. 
The beneficial effect of modified NC-FET luteal support protocol on pregnancy 
outcomes also sustained in the re-analysis of the data (Orvieto et al., 2016).  
Artificial cycle FET 
The positive effect of a single dose mid-luteal GnRH agonist supplementation to 
hormonally substituted cycles was first demonstrated by Tesarik et al. (2004) on 
oocyte recipients. Recipients were prepared according to the AC-FET protocol, 
whereas embryo was attained from the oocyte donor after COH performed 
according to the agonist protocol. Oocytes from one donor were equally shared 
by two recipients, and these recipients were randomized to receive either placebo 
or GnRH agonist in addition to progesterone. Fresh ET of cleavage stage embryo 
was performed into the hormonally prepared uterus of the recipient. IR was 
found to be increased in the intervention group, whereas the difference of 12.3 
percentage points in LBR pointing to the benefit of GnRH agonist use remained 
but was statistically insignificant. 
To date, three RCTs on mid-luteal GnRH agonist supplementation additional to 
progesterone in AC-FET cycles have been conducted. Davar et al. (2015) used 
repeated dosages of ASA along with estradiol supplementation, and 200 women 
were randomized to receive either progesterone only or an additional single dose 
of GnRH agonist three days after FET. The IRs were similar between the groups, 
and the difference of 5 percentage points in ongoing PR favoring GnRH agonist 
supplementation remained insignificant. The results were in line with the most 
recent RCT by Ye et al. (2019), in which a total of 868 AC-FET cycles were 
randomized to receive a single dose of mid-luteal GnRH agonist or standard 
HRT. The difference in IR favoring GnRH agonist administration was only seen 
in the subgroup of women over 35 years old (Ye et al., 2019). In an RCT by 
Zarei et al. (2017), women undergoing AC-FET were randomized into four 
groups to receive luteal support with vaginal progesterone (n=100), oral 
40 Review of literature 
dydrogesterone (n=100), vaginal progesterone combined with a single dose of 
GnRH agonist (n=100), and oral dydrogesterone combined with hCG (n=100). 
Ongoing PR was compromised in the group using oral dydrogesterone, whereas 
no difference was observed among the other groups. However, there were 
inconsistencies in the reported results, and the quality of the study was 
questionable. 
2.4.5 Safety of GnRH agonist administration in the luteal phase 
Safety data of GnRH agonist on neonatal outcomes is based on previous reports 
of normal pregnancies and healthy neonates born after intended or inadvertent 
exposure to luteal phase GnRH agonist (Abu-Heija et al., 1995, Cahill et al., 
1994, Chardonnens et al., 1998, Gartner et al., 1997, Marcus and Ledger, 2001). 
None of the studies evaluating single or continuous use of short-acting GnRH 
agonist as LPS in addition to progesterone in fresh ET or FET cycles have 
included neonatal data in the study outcomes.  
2.5 Quality of evidence and open questions 
Earlier data on the developmental capacity of MN embryos suggested very poor 
pregnancy potential but has been contradicted by newer studies. All in all, data 
on the pregnancy and obstetric outcomes of the BN/MN embryos are still scarce. 
Since the BN/MN embryos are often deselected from ET, evidence regarding the 
significance of blastomere multinucleation has remained limited. Therefore, it is 
still an open question of whether BN/MN embryos are safe to transfer or suitable 
for cryopreservation. 
The heterogeneity in the LPS regimens in different studies generates limitations 
on the interpretation of the results. In three meta-analyses conducted on the 
subject, a mid-luteal single dose of GnRH agonist improved IR, CPR, ongoing 
pregnancies, and LBR, especially in the antagonist ICF/ICSI cycles. However, 
the overall quality of evidence is too low to draw clear conclusions on the 
potential effect of mid-luteal GnRH agonist supplementation (Kyrou et al., 2011, 
Martins et al., 2016, Oliveira et al., 2010). Evidence on the effect on mid-luteal 
use of GnRH agonist in FET cycles is even more limited. However, the policy of 
using GnRH agonist as luteal support is adopted widely in clinical use. Further 
studies are warranted to provide information about the clinical relevance of 
GnRH agonist as luteal support. 
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3 AIMS OF THE STUDY 
This thesis was designed to study the significance of embryo quality and 
modified luteal support regarding the results of FET cycles. Regarding embryo 
quality, multinucleation was the focus of interest. More specifically, the 
occurrence and contributing factors of multinucleation in frozen-thawed embryo 
cohorts and the effect of multinucleation on the course of pregnancy and neonatal 
health were explored. Furthermore, in the present study, the effect of the short-
acting GnRH agonist, triptorelin, as additional adjuvant therapy in the mid-luteal 
phase of FET cycles was evaluated. 
The specific aims were as follows: 
1 To evaluate the de novo occurrence of embryo multinucleation before and 
after embryo cryopreservation and assess whether the presence of BN/MN 
embryos in an embryo cohort before cryopreservation was associated with 
a higher occurrence of multinucleation after thawing (Study II). 
2 To assess whether female age or ovarian response to COH was associated 
with de novo occurrence of multinucleation before and after embryo 
cryopreservation (Study II). 
3 To study pregnancy results, obstetric outcomes, and health of the 
newborns in FET cycles using BN/MN embryos (Studies I and III).  
4 To study whether a single subcutaneous dose of GnRH agonist (triptorelin) 
administered at the mid-luteal phase of NC- or AC-FET cycles could 
improve pregnancy outcomes (Studies IV and V).  
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4 MATERIALS AND METHODS 
4.1 Study populations and study designs 
This thesis consists of five publications. Study I: A case report of CT after the 
transfer of an MN frozen-thawed embryo. Studies II-III: Two historical cohorts 
representing the occurrence of multinucleation in frozen-thawed embryo cohorts, 
clinical factors related to the formation of multinucleation as well as pregnancy 
and obstetric outcomes of BN and MN FETs. Studies IV-V: A prospective 
randomized clinical pilot study (Study IV) and a prospective interventional study 
(Study V) evaluating the effect of a single dose of triptorelin as an additional 
LPS in NC- and AC-FET cycles. The information of data collection times and 
locations, as well as inclusion and exclusion criteria, are described in Table 3. 
Table 3. Study period, location, and inclusion and exclusion criteria. 
Study I 
Year 2013 
Turku University Hospital, Turku, Finland 
Inclusion criteria: 
A case of conjoined twins after transfer of frozen-thawed MN embryo 
Exclusion criteria: 
None 
Study II 
January 2010 − December 2012 
Turku University Hospital, Turku, Finland 
Inclusion criteria: 
415 consecutive IVF/ICSI cycles and embryo cryopreservation and frozen embryo transfers until 4/2014 
Subanalysis: Multinucleation in embryo cohorts with or without embryo cryopreservation (2012) 
Exclusion criteria: 
None 
Study III 
January 2009 − December 2015 
Turku University Hospital, Turku, Finland  
Inclusion criteria: 
Case group: Single or double BN or MN FET 
Control group: Single or double mononucleated FET 
Subanalysis: Pregnancy outcomes of BN vs. MN FET 
Exclusion criteria: 
Indistinct documentation on blastomere multinucleation 
Subanalysis: double FETs including BN and MN embryos 
Study IV-V 
May 2013 − December 2014 
Turku University Hospital, Turku, Finland and Väestöliitto Fertility Clinic1, Turku, Finland (Study IV)  
Turku University Hospital, Turku, Finland and Tampere University Hospital, Tampere, Finland (Study V)  
Inclusion criteria: 
Scheduled NC FET (Study IV) or AC-FET (Study V) 
Duration of infertility ≥ 12 months 
Exclusion criteria: 
Female age > 42 years at the time of embryo freezing 
Female or male chromosomal abnormality, use of testicular or donated sperm without female cause 
for infertility, use of donated oocytes 
Congenital uterine anomalies, intramural myomas (> 4 cm) 
Pathologies distorting the uterine cavity 
Endometrium thickness < 6 mm prior to FET 
Untreated thyroid dysfunction or hyperprolactinemia 
Allergy to triptorelin 
IVF = in vitro fertilization, ICSI = intracytoplasmic sperm injection,  
FET = frozen embryo transfer, BN = binucleated, MN = multinucleated, 
NC = natural cycle, AC = artificial cycle 
1Now Mehiläinen Felicitas 
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4.1.1 Study I 
Study I was a case report of CT pregnancy after a transfer of MN frozen-thawed 
embryo. A 33-year-old healthy woman and a 37-year-old man suffered from 
infertility due to azoospermia after stem cell transplantation for hematologic 
malignancy. Sperm was frozen before the malignancy treatment and used for ICSI. 
An antagonist protocol (Gonal-F 175 IU for 9 days and Cetrotide 0.25 mg for 6 days) 
was followed for COH and out of 10 obtained oocytes, eight fertilized normally. At 
the 2-cell stage, all embryos contained MN blastomeres, and after cleavage at the 4-
cell stage, each embryo eligible for freezing carried either one BN or MN blastomere. 
The slow freezing method was used for embryo cryopreservation. After an 
unsuccessful transfer of a fresh mononucleated 4-cell stage embryo, FET was 
performed during NC. An 8-cell embryo containing three MN blastomeres was 
selected for transfer after overnight culture of three thawed embryos. 
4.1.2 Studies II and III 
Studies II - III involved a retrospective analysis of prospectively collected data 
from Turku University Hospital medical records and IVF laboratory documents. 
Data included detailed information on the embryo classification, freezing, and 
thawing methods, as well as the demographics of the women and characteristics 
of the IVF/ICSI and FET cycles. 
Study II consisted of 415 consecutive IVF/ICSI cycles with embryo 
cryopreservation by slow freezing. Data on embryo thawing and post-thaw culture 
was tracked until the end of April 2014. Drop out in sample data included 
cryopreserved but not thawed embryos (n=2227) as well as embryos that had 
degenerated during the thawing process (n=143) (Figure 7). Data on objectively 
measurable parameters known to reflect ovarian competence during gonadotropin 
treatment were retrieved from medical records and included female age at the time 
of oocyte pick up, IVF/ICSI stimulation protocol, number of retrieved oocytes, 
consumption of total recombinant FSH or human menopausal gonadotropin, and the 
proportional dose of FSH or human menopausal gonadotropin per obtained oocyte. 
Due to the difference in pharmacokinetic profiles, cycles stimulated with 
corifollitropin alfa (n=25) were not included in the analysis of FSH consumption. 
Two additional approaches were used to further analyze associations between 
clinical factors and the occurrence of multinucleation: IVF/ICSI cycles were divided 
into three groups according to the female age (20−29 years, 30−35 years and 36−40 
years) and assessed in relation to number of harvested oocytes (1−8; 9−17; ≥18) and 
proportional FSH used per harvested oocyte (1− 84 IU, 85−237 IU and ≥ 238 IU). 
Division to the categories for oocyte number and FSH consumption per collected 
oocyte was defined from upper and lower quartiles of the data distribution.  
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  Flowchart of the study II  ≥ one MN embryo/ embryo cohort 
 MN embryos/ 
all embryos 
D2 
  No of 415 IVF/ICSI cycles: 415   62.4% (259/415)   16.7% (572/3430)  No of embryos: 3430   
            
D2t 
               
  No of embryo cohorts with thawing: 330       
 No of thawed embryos: 1203       
              
                 
  No of embryo cohorts with survived embryos: 320   16.3% (52/320)   5.8% (61/1060)  No of survived embryos: 1060     
             
D3t 
              
  No of embryo cohorts with overnight culture: 265   31.7% (84/265)   14.9% (108/771)  No of cultivated embryos after thawing: 771   
D2: day of embryo culture 
D2t: day of thawing 
D3t: day after thawing and an overnight culture 
Figure 7. Number of IVF/ICSI cycles and de novo occurence of multinucleation in embryo 
cohorts and embryos at each time point of evaluation. 
Compared to 2010 and 2011, the database from 2012 was more comprehensive 
and included information about IVF/ICSI cycles not eligible for 
cryopreservation. These data provided an opportunity to evaluate whether the 
incidence of MN was different in IVF/ICSI cycles with cryopreservation (n=137) 
compared to cycles without freezing (n=58). 
For Study III, 1,335 frozen-thawed ETs were evaluated from the IVF laboratory 
documents, and single and double ETs comprised exclusively of BN/MN embryos 
(n=136) were included in the Case group. The Control group (n=136) consisted of 
randomly selected ETs of mononucleated embryos among women matched for age 
at the time of oocyte pick up. Also, a sub-analysis of pregnancy results of FETs 
containing either BN or MN embryos exclusively were conducted. FET protocols 
included NC, AC, and OI cycles with clomifene citrate or low dose gonadotropin. 
Demographics of the women and cycle characteristics are presented in Table 4. 
Standard LPS with vaginal micronized progesterone 200mg twice daily was 
administered in natural and OI cycles. In AC-FET, standard HRT included oral or 
transdermal estrogen combined to 600 mg vaginal micronized progesterone when 
the endometrial thickness was at least 6 mm and the absence of a dominant follicle 
was determined with vaginal ultrasound. Data on the course of pregnancy and 
health of the newborns were obtained from the medical records. 
4.1.3 Studies IV and V 
Study IV was a prospective randomized clinical pilot study and Study V, a 
prospective interventional pilot study. Demographics of the women and cycle 
characteristics are presented in Table 4. 
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Table 4. Demographics of the women and cycle characteristics. 
  Study III Study IV Study V 
  Case Control Intervention Control Intervention Control 
N 136 136 65 62 72 72 
  Mean (SD) 
Female age at OPU 32.3 (4.2) 32.5 (4.3) 33.0 (3.8) 34.0 (5.7) 31.9 (3.6) 32.5 (3.7) 
BMI (kg/m2)   24.1 (3.9) 24.0 (3.7) 23.2 (3.3) 23.8 (3.4) 24.0 (4.0) 24.3 (4.5) 
No of previous pregnancies  0.8 (1.2) 0.6 (1.0) −− −− −− −− 
No of previous deliveries     0.3 (0.6) 0.3 (0.6) −− −− −− −− 
Antral follicle count 21 (10.4) 19 (9.2) −− −− −− −− 
Number of transferred embryos 1.1 (0.3) 1.1 (0.3) 1.1 (0.4) 1.1 (0.3) 1.1 (0.3) 1.1 (0.2) 
Endometrial thickness  (mm) −− −− 9.7 ± 2.0 9.1 ± 1.8  9.7 (2.0) 9.1 (1.8) 
Duration of infertility at OPU  47.7 (23.9) 47.4 (30.9) 42.0 (27.6) 42.1 (31.1) 41.0 (22.4) 43.1 (24.6) 
   n (%) 
Primary infertility 71 (52.2) 89 (65.4) 36 (55.4) 35 (56.5) 32 (44.4) 34 (47.2) 
Etiology for Infertility             
     Female only   58 (42.7) 64 (47.1) 22 (33.4) 31 (50.0) 39 (54.2) 39 (54.2) 
     Male  42 (30.9) 32 (23.5) 16 (24.6) 17 (27.4) 10 (13.9) 9 (12.5) 
     Combined  23 (16.9) 15 (11.0) 10 (15.4) 3 (4.8) 11 (15.3) 12 (16.7) 
     Unknown  12 (8.8) 24 (17.7) 17 (26.2) 11 (17.7) 12 (16.7) 10 (13.9) 
     Not available 1 (0.7) 1 (0.7) 0 0 0 2 (2.8) 
Long stimulation protocol 76 (55.9) 75 (55.1) 35 (53.8) 35 (56.5) 27 (37.5) 27 (37.5) 
Live birth from fresh ET 30/125 (24.0) 24/124 (19.4) −− −− −− −− 
All embryos frozen (n) 11 12 −− −− −− −− 
FET during natural cycle 79 (58.0) 95 (69.9) 65 (100) 62 (100) −− −− 
FET during artificial cycle 55 (40.4) 41 (30.1) −− −− 72 (100) 72 (100) 
FET during ovulation induction 2 (1.5) 0 −− −− −− −− 
Single embryo transfer 121/136 (89.0) 119/136 (87.5) 56/65 (86.2) 54/62 (87.1) 65/72 (90.3) 68/72 (94.4) 
FET at cleavage stage 130 (95.6) 126 (92.6) 65 (100) 62 (100) 40 (55.6) 42 (58.3) 
Completely survived embryos 116/151 (76.8) 118/153 (77.1) 58/74 (78.4) 58/70 (82.9) 68/80 (85.0) 73/76 (96.0) 
Normally cleaved embryosa 77/122 (63.1) 74/109 (67.9) 33/57 (57.9) 34/53 (64.2) 54/59 (91.5) 51/58 (87.9) 
Detection of BN/MN              
2 − cell stage  1/151 (0.7)          
4 − cell stage 63/151 (41.7)           
8 − cell stage 87/151 (57.6)           
Values are mean (SD) unless otherwise indicated 
aNormal cleavage defined as doubled blastomere number after an overnight culture 
BMI= body mass index, ET= embryo transfer, FET= frozen embryo transfer, OPU= oocyte pick up, BN= bi-
nucleation, MN= multinucleation 
 
Study IV included 98 women scheduled for NC-FET and Study V 107 women 
scheduled for AC-FET. Selection of the intervention treatment was carried out 
using sealed opaque envelopes. Women randomized to NC-FET Control group 
received standard LPS and women randomized to the AC-FET Control group 
underwent standard HRT as noted above in the description of Study III. In both 
intervention arms, an additional single dose of triptolerin 0.1 mg was administered 
subcutaneously when the age of the transferred embryos reached six days.  
In NC-FETs, vaginal ultrasound assessment was performed in the preovulatory phase 
to identify the dominant follicle growth, and in AC-FET, the absence of a dominant 
follicle was determined. Endometrial thickness of at least 6 mm was confirmed 
before proceeding to NC-FET or progesterone supplementation in AC-FET. In NC-
FET, ovulation was determined using commercial urine-based ovulation kits, and 
standard LPS administration was started when the embryonic age reached three days. 
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Standard LPS was continued until the pregnancy test in NC-FET, whereas in AC-
FET, HRT was continued until the ninth week of gestation or a negative pregnancy 
test. When no ongoing pregnancy occurred, and surplus embryos were available, a 
second attempt with crossover design was scheduled (Figure 8).  
 
Figure 8. Flowchart of the study population, Studies III and IV. 
In Study IV, an analysis of β-hCG- concentrations from plasma samples by 
electrochemiluminence immunoassay (Cobas 8000, Roche Diagnostics GmbH, 
Mannheim, Germany) was performed when the embryonic age reached 16 days.  
4.2 Laboratory methods 
4.2.1 Embryo assessment (Studies I-III) 
Blastomere number and evenness, fragmentation, and the nuclei of the embryos 
were systematically evaluated before cryopreservation (D2), within one hour 
after thawing (D2t) and 23-25 hours after thawing (D3t). Embryo assessment was 
performed simultaneously by two experienced observers, one via inverted mic-
roscope (Nikon Diaphot 300) with 400× magnification and the other via a 
connected PC monitor, and in case of discrepancy in embryo grading repeated for 
consensus. In Study II, embryos were graded as either mononucleated or MN (two 
or more nuclei detected in at least one blastomere). Because the objective was to 
assess the de novo occurrence of multinucleation at each time point of evaluation, 
all MN embryos detected on D2 or D2t were excluded from further analysis. 
Control Intervention Control Intervention
Exclusion, pregnant 
or no surplus embryos
Control Intervention Control Intervention
Total no of FET cycles 62 65 72 72
Participans 
Crossover Crossover
N
N
Exclusion
Randomisation
2 0
25 28 33 33
20 17 21 18
Study III Study IV
42 48 51 54
6 2
48 50 51 56
98 107
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In Study III, embryos were classified as mononucleated, BN, or MN according 
to the nuclear status of the embryos (Figure 9). Embryos exhibiting BN/MN 
before or after cryopreservation were grouped together due to the limited number 
of cases. If there was no blastomere loss after thawing, embryos were rated as 
“completely survived”. Resumption of mitosis was classified as normal if the 
number of blastomeres had doubled during an overnight culture following 
thawing. BN/MN embryos were transferred if normal embryos of good quality 
were not available. A maximum of two embryos was transferred per FET cycle.  
 
 
 
 
Figure 9. Definition of nuclear abnormalities (Study III). 
Mononucleated embryo Single nucleus in each blastomere (A)
Binucleated embryo Two evenly sized nuclei in ≤25% of blastomeres (B)
Multinucleated embryo
1. Embryos with multiple nuclei (C)
or
2. Two unevenly sized nuclei in one or more 
blastomeres (D)
or
3. Two evenly sized nuclei in >25% of the 
blastomeres (E)
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Eligibility criteria for embryo cryopreservation included less than 25% 
fragmentation or difference in blastomere size. BN/MN embryos were not 
automatically excluded from cryopreservation if general criteria were met.  
4.2.2 Embryo freezing and thawing  
During the period covering Studies I-V (2009-2015) embryo cryopreservation in 
the Turku University Hospital was performed using a slow freezing protocol. A 
slow freezing cryopreservation kit (Sydney IVF Cryopreservation kit, K-SICS-
5000, Cook Australia 2009-2013 and Freeze Kit Cleave, 10166, Vitrolife Sweden, 
2014-2015) was used according to the manufacturer’s protocol and the cooling 
rate was controlled with a freezer (Planer Kryo 10-MRV, Planer PLC, Sunbury 
on Thames, UK). The thawing was performed by rapid warming in a 30°C water 
bath and rehydration in a series of media with decreasing cryoprotectant 
concentrations (Sydney IVF Thawing Kit, K-SITS-5000, Cook Australia years 
2009-2013 and Thaw Kit Cleave, 10167, Vitrolife Sweden years 2014-2015). 
Afterwards, the embryos were incubated for 5 minutes in a cryopreservation 
buffer at RT, and subsequently, the dish was placed for 5 minutes on a heated 
stage at 37 °C. If feasible, the embryos were cultured overnight (Sydney IVF, K-
SICM-50, Cook Australia years 2009-2012 and G-1-Plus medium, 10128, 
Vitrolife Sweden years 2013-2015) in 7% CO2, 8% O2, and 85% N2 at 37±0.1°C.  
In the Väestöliitto Fertility Clinic (now Mehiläinen Felicitas), Turku embryos 
were cryopreserved using the slow freezing protocol (Study IV). 
Cryopreservation and thawing kits were used according to the manufacturer’s 
protocol (Freeze Kit Cleave and Thaw Kit Cleave, Vitrolife Sweden) and cooling 
rate was controlled using Planer Kryo 360-1.7. Embryo cryopreservation method 
in the Tampere University Hospital (Study V) included vitrification of embryos 
using Vitri Freeze Kit ES, Fertipro, Belgium, and thawed using Vitri Thaw Kit 
ES, Fertipro, Belgium. 
4.3 Statistical analyses 
The main aspects of the statistical analyses in sub-studies are described in Figure 
10. The statistical significances of the differences between frequency 
distributions were tested with Pearson’s chi-squared or Fisher’s exact test for 
categorical variables and with Student’s t-test for continuous variables with a 
normal distribution. Normality of the distributions was evaluated visually and 
with Shapiro-Wilk’s test. Odds ratios and 95% confidence intervals (CIs) were 
calculated using univariable and multivariable binary logistic regression analysis.  
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Figure 10. Statistical analyses. 
In Study III, stratified logistic regression analysis and linear mixed models were 
used in the analyses to take account the matching of cases and controls. 
STUDIES IV-V 
Outcome measures: 
Pregnancy outcomes in natural and artificial frozen embryos transfer cycles after 
administration of luteal phase single-dose triptolerin 
Statistical analyses: 
SPSS software system for Windows, versions 22 and 23 
1. Carryover effect: Logistic regression analysis  
2. Logistic regression analysis with generalized estimation equalition extension was 
applied. Results are adjusted for maternal age at COH and duration of infertility (Studies 
IV-V) and cryopreservation method and embryonic age at the time of FET (Study V) 
3. β-hCG- concentrations: Student’s t-test 
STUDY III 
Outcome measures: 
1. Pregnancy and obstetric outcomes, obstetric complications and health of the newborns after 
transfer of mononucleated or bi/multinucleated frozen-thawed embryo 
2. Reproductive potential of bi- vs. multinucleated embryos 
3. Subanalysis: Pregnancy outcomes of bi- vs. multinucleated embryos 
Statistical analyses: 
JMP Pro, Version 12 and SAS System for Windows, version 9.4 
1. Categorical variables: Pearson’s chi-squared or Fisher’s exact test 
2. Continuous variables: Student’s t-test 
3. Multivariable logistic regression was used to adjust for duration of infertility, BMI, 
degree of blastomere survival, resumption of mitosis, and number of transferred embryos 
4. Birth weight was analyzed using the linear mixed model, adjusted for BMI 
Statistical analyses 
STUDY II 
Variables: 
Dependent variable: Blastomere multinucleation in an embryo cohort  
Independent variables: Female and male age, total and proportional FSH consumption, 
number of retrieved oocytes  
Statistical analyses: 
SAS version 9.4 (SAS Institute, Cary, NC, USA) 
1. Differences in frequency distributions: Pearson’s Chi Square  
2. Univariable binary logistic regression analysis was used to assess the associations 
between the dependent and the independent variables  
3. Multivariable binary logistic regression analysis included the independent variables 
showing significance in the univariate analysis 
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For Studies IV-V, analysis was conducted on the FET cycle level for all cycles, 
and the carryover effect was first tested using a logistic regression model. A 
logistic regression model was applied with generalized estimation equations to 
account for dependence among repeated treatments. Statistical significance was 
set at p<0.05. Statistical analyses were performed using SAS System for 
Windows, Version 9.4 (SAS Institute Inc, Cary, NC, USA); (Study II-III), JMP 
Pro, Version 12 (Study III); SPSS software (IBM SPSS Statistics for Windows, 
Versions 22.0 (Study IV) and 23.0 (Study V). 
4.4 Ethics 
Written informed consent for publication of the case report (Study I) was given 
by the patient. Study II had approval from the Joint Ethics Committee of Turku 
University Hospital (117/1801/2013), and Studies III-V from the Ethical 
Committee of the Hospital District of Southwest Finland (Study III 
34/1801/2014 and Studies IV-V: 36/1800/2013). For Studies IV-V, each 
participant signed a written informed consent (Clinical Trials study number 
NCT02620124). 
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5 RESULTS 
5.1 De novo occurrence of MN embryos before freezing, after 
thawing and after overnight culture (Study II) 
De novo occurrence of multinucleation was evaluated among embryos and embryo 
cohorts before freezing, after thawing and after an overnight culture after thawing 
(Figure 7). Embryo multinucleation was most common before freezing. 
Accordingly, the occurrence of multinucleation in embryo cohorts was more 
prominent before freezing than after an overnight culture after thawing (p<0.001). 
The presence of MN embryos in an embryo cohort before freezing (D2) was not 
associated with de novo multinucleation in sibling embryos after thawing (D2t) 
(p=0.113) or after an overnight culture after thawing (D3t) (p=0.845).  
In the sub-analysis of the IVF/ICSI cycles (2012), the overall incidence of 
multinucleation before freezing (D2) was similar between the cycles with 
(n=137) or without (n=58) cryopreservation (66.4% vs. 70.7%, p= 0.560). 
5.2 Multinucleation in embryo cohorts, female age and ovarian 
response (Study II) 
The mean age of the women at the time of ovum pickup was 33 ± 4 years (range 23-
40). The frequency of MN embryos decreased steadily along with increasing female 
age (OR for four years increase in female age: 0.69 [95% CI 0.56-0.85, p<0.001]). 
To further explore the effect of female age and ovarian response, embryo cohorts 
were divided into three groups according to the female age (20−29 years, 30−35 
years and 36−40 years). An interaction between the presence of MN embryos, 
female age, and the number of harvested oocytes (p<0.001) was detected on day 
two of embryo culture before freezing (D2): the frequency of MN embryos was the 
lowest in older women with a low number of collected oocytes. For a more detailed 
analysis, the three female age categories were divided into subgroups based on the 
number of retrieved oocytes (1−8; 9−17; ≥18). MN embryos were most frequently 
observed in the age group of 20−29 years, and in this age group, the occurrence was 
not associated with the number of retrieved oocytes. On the contrary, in the age 
groups of 30-35 years and 36-40 years, an association between high ovarian res-
ponse and blastomere multinucleation in embryo cohorts was seen (Table 5). Notab-
ly, these associations were only seen before cryopreservation (D2) and disappeared 
after thawing (D2t) (p=0.964 and p=0.551, respectively) and after an overnight 
culture after thawing (D3t) (p=0.806 and p=0.189, respectively). Furthermore, at 
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these points of evaluation, no interaction effect between multinucleation and number 
of collected oocytes (p=0.926 and p=0.405) was detected in any age group. 
Table 5. Multinucleation on day-2 of embryo culture in relation to female age and number 
of obtained oocytes per ovum pick up (Study II). 
Female age 
(years) 
No. of 
IVF/ICSI 
cycles 
No of oocytes 1−8 
% (n/n)a 
n= 95 
No of oocytes 9−17 
% (n/n)a 
n=214 
No of oocytes > 17  
% (n/n)a 
n=106 
p-valueb 
20 − 29 87 69.2 (9/13) 72.5 (29/40) 79.4 (27/34) NS 
30 − 35 207 38.5 (15/39) 69.2 (81/117) 78.4 (40/51) <0.001 
36 − 40 121 20.9 (9/43) 59.7 (34/57) 71.4 (15/21) <0.001 
aNo. of embryo cohorts with multinucleation/all cohorts in a subgroup in parentheses 
bChi Square test  
IVF = in vitro fertilization, ICSI = intracytoplasmic sperm injection, FSH = follicle stimulating hormone 
A similar pattern in the occurrence of MN embryos in embryo cohorts was detected 
when FSH consumption was taken into account. Before cryopreservation (D2), the 
occurrence of multinucleation decreased with an increase in the total and 
proportional FSH consumption, but the association vanished after thawing (D2t) and 
after overnight culture after thawing (D3t) (Table 6). An interaction between female 
age, proportional FSH consumption, and the presence of MN embryos were also 
seen when the study group was further divided into age groups (p=0.003). In line 
with the associations detected between female age and number of retrieved oocytes, 
no difference on the occurrence of MN embryos was detected in the age group of 
20−29 years, whereas in women aged 30-35 years and 36-40 years MN embryos 
were more common when the proportional dose of FSH was low. In the most 
advanced age group of 36-40 years, a similar association was also detected after 
thawing (D2t) and after an overnight culture after thawing (D3t) (Table 7).  
Table 6. Multinucleation in relation to total and proportional FSH consumption in IVF/ICSI 
cycles on day-2 of embryo culture (D2), after thawing (D2t) and on day-3 of embryo culture 
after thawing (D3t) (Study II). 
Time 
point of 
embryo 
evaluation 
  
Embryo cohorts 
without 
multinucleation 
Embryo 
cohorts with 
multinucleation 
p-
valuea OR (95% CI)  
D2 
No. of IVF/ICSI cycles 146 244    
FSH dose (IU) 2167.4 ± 899.1 1815.5 ± 721.4 <0.001 0.65 (0.52-0.80) 
Prop. FSHb  275.4 ± 237.2 144.6 ± 116.9 <0.001 0.36 (0.36-0.50) 
      
D2t 
No. of IVF/ICSI cycles 255 46    
FSH dose (IU) 1980.7 ± 815.5 1882.3 ± 761.0 NS 0.89 (0.63-1.23) 
Prop. FSHb  199.5 ± 190.5 167.3 ± 193.9 NS 0.81 (0.55-1.20) 
      
D3t 
No. of IVF/ICSI cycles 177 81    
FSH dose (IU) 1987.7 ± 815.5 1893.2 ± 763.0 NS 0.88 (0.67-1.17) 
Prop. FSHb  201.9 ± 179.7 158.3 ± 144.4 NS 0.71 (0.49-1.02) 
Numbers are mean ± SD 
aLogistic regression analysis 
bProportional FSH (IU/oocyte) 
IVF/ICSI cycles stimulated with corifollitropin excluded from the analysis (n=25) 
FSH= follicle stimulating hormone, IVF=, in vitro fertilization, ICSI, intracytoplasmic sperm injection 
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Table 7. Multinucleation in relation to proportional FSH consumption and female age in 
IVF/ICSI cycles on day-2 of embryo culture (D2), after thawing (D2t), and on day-3 of 
embryo culture after thawing (D3t) (Study II). 
Time 
point of 
embryo 
evaluation 
Female 
age 
(years) 
No. of 
IVF/ICSI 
cycles  
Categories of proportional FSH 
consumption, % (number of embryo 
cohorts with multinucleation/ all cohorts 
in the subgroup) 
p-
valuea OR (95% CI) 
1 − 84 IU/ 
oocyte 
85 − 237 IU/ 
oocyte 
≥ 238 IU/ 
oocyte 
D2 
20 − 29 86 81.1 (30/37) 71.1 (27/38) 72.7 (8/11) NS 0.95 (0.53-1.69) 
30 − 35 195 88.2 (45/51) 63.6 (68/107) 40.5 (15/37) <0.001 0.25 (0.13-0.47) 
36 − 40  109 75.0 (6/8) 59.6 (31/52) 28.6 (14/49) <0.001 0.35 (0.20-0.63) 
        
D2t 
20 − 29 73 25.8 (8/31) 9.4 (3/32) 20.0 (2/10) NS 1.33 (0.75-2.35) 
30 − 35 142 12.8 (5/39) 13.2 (10/76) 11.1 (3/27) NS 0.87 (0.44-1.71) 
36 − 40 86 37.5 (3/8) 23.1 (9/39) 7.7 (3/39) 0.033 0.33 (0.12-0.91) 
        
D3t 
20 − 29 60 46.4 (13/28) 16.0 (4/25) 57.1 (4/7) NS 0.89 (0.30-2.67) 
30 − 35 120 28.1 (9/32) 29.2 (19/65) 21.7 (5/23) NS 0.83 (0.49-1.42) 
36 − 40 78 75.0 (6/8) 34.3 (12/35) 25.7 (9/35) 0.028 0.47 (0.20-0.90) 
aLogistic regression analysis   
IVF/ICSI cycles stimulated with corifollitropin excluded from analysis (n=25) 
IVF = in vitro fertilization, ICSI = intracytoplasmic sperm injection, FSH = follicle stimulating hormone 
5.3 Pregnancy and perinatal outcomes after transfer of BN or MN 
frozen-thawed embryos (Study III) 
Univariate analysis was first carried out to test differences in pregnancy 
outcomes between the Case and the Control groups. IR, CPR, ongoing PR at 
gestational week 12 and LBR were lower in the Case group than in the Control 
group (28.0% and 39.3%, p = 0.036, 29.4% and 44.1%, p = 0.012, 22.8% and 
36.0%, p = 0.017, and 22.1% and 36.0%, p = 0.011, respectively). However, no 
difference in miscarriage rate was detected (20.0% vs. 15% in the Case and the 
Control group, respectively). Multivariable logistic regression analysis confirmed 
the differences in CPR and LBR and similar miscarriage rate between the Case 
and the Control groups after adjusting for confounding factors. The birth weights 
in all newborns in both the Case and the Control groups were appropriate for 
gestational age. No difference in perinatal outcomes (gender distribution, 
placental weight, CAs, and the occurrence of obstetric complications) was 
observed. Clinical outcome data are presented in Table 8, and detailed 
information on the CAs detected in the Case and the Control group are shown in 
Figure 11.  
Table 8. Pregnancy, obstetric and perinatal outcomes (Studies III, IV and V). 
  Study III Study IV Study V 
   Case (n = 136) 
Control 
(n = 136) 
p- 
value  
OR  
(95% CI) 
Intervention  
group 
(n = 65) 
Control 
group 
(n = 62) 
p- 
value 
OR 
(95% CI) 
Intervention  
group 
(n = 72) 
Control 
group 
(n = 72) 
p- 
value 
OR  
(95% CI) 
  n (%) 
Live birth 30 (22.1) 49 (36.0) 0.038j 0.48            (0.24 − 0.96) 20 (30.8) 15 (24.2) NS
k,l 1.37           (0.27 − 3.28) 21 (29.2) 14 (19.4) NS
k,m 1.76 (0.87−3.56) 
Implantation ratea 42/151          (27.8) 
61/153          
(39.9) 0.011
j 0.39            (0.19 − 0.81) −− −−     −− −−     
Clinical pregnancy 40 (29.4) 60 (44.1) 0.012j 0.40          (0.19 − 0.82) 25 (38.5) 17 (27.4) NS
k,l 1.65          (0.77 − 3.55) 29 (40.3) 26 (36.1) NS
k,m 1.13 (0.63−2.03) 
Miscarriageb 8 (20.0) 9 (15.0) NSj 1.39          (0.44 − 4.35) 3 (12.0) 2 (11.8) NS
k 1.13         (0.20 − 6.52) 8 (27.6) 11 (42.3) NS
k 2.15 (0.20−22.78) 
Ongoing pregnancy at gwk 
12 31 (22.8) 49 (36.0) 0.017
f,i 0.52         (0.31 − 0.89)  −− −−     −− −−     
Extrauterine pregnancyb 1 (2.5) 2 (3.3)e     2 (8.0) 0 (0.0)e     0 (0.0) 1 (3.8)e     
Induced abortiona 1 (2.5) 0 (0.0)e    0 (0.0) 0 (0.0)e   0 (0.0) 0 (0.0)e    
Congenital malformationsc 3 (9.7) 2 (4.1) NSg,i 2.52          (0.40 − 16.00) −− −−     −− −−     
Sex of the infant                
Male 16 (51.6) 23 (46.0) NSf,i 0.80  −− −−     −− −−     Female 15 (48.4) 27 (54.0) (0.33 − 1.96) −− −−     −− −−     
Obstetric complicationsc 6 (20.0) 10 (20.4) NSg,i            
Pre-eclampsia  0 (0.0) 2 (4.1) NSg,i   −− −−     −− −−     
GDM 6 (20.0) 8 (16.3) NSg,i   −− −−     −− −−     
  mean ± SD 
Birth weightd 3526 ± 689 3632 ± 420 NSh,i  3519 ± 551 3807 ± 341 NSh,i   3600 ± 580 3666 ± 373 NSh,i   
Placental weightd 610 ± 139 603 ± 132 NSh,i   −− −−     −− −−     
aNo. of gestational sacs per total no. of transferred embryos, bPercentage from clinical pregnancies, cCalculated from ongoing pregnancies, dOnly singleton pregnancies included in the 
analysis, eInsufficient data for statistical analysis, fPearson's Chi-square, gFisher's exact test, hStudent's t-test, iUnivariate analysis, jMultivariable analysis adjusted for body mass index, 
duration of fPearson's Chi-square, gFisher's exact test, hStudent's t-test, iUnivariate analysis, jMultivariable analysis adjusted for body mass index, duration of infertility, number of 
transferred embryos infertility, blastomere loss and resumption of mitosis, kLogistic regression analysis, generalized estimating equalitions, lAdjusted for maternal age at oocyte pick up 
and duration of infertility mAdjusted for maternal age at oocyte pick up, duration of infertility, cryopreservation method and embryonic age at the time of frozen embryo transfer 
Gwk= gestational week, GDM= gestational diabetes mellitus 
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Single embryo transfer:
Binucleated embryo
Congenital anomaly:
Enlarged sinus coronarius and 
left-sided vena cava superior
Pregnancy outcome:
Vaginal delivery of male infant 
at gestational week 40
Single embryo transfer:
Multinucleated embryo 
Congenital anomaly:
Conjoined twins 
Pregnancy outcome:
Termination of pregnancy at 
gestational week 12
Double embryo transfer:
Bi- and multinucleated
embryo
Congenital anomaly:
Cleft palate, pulmonary 
stenosis
Chromosomal abnormality:
A  deletion in a long arm of 
chromosome 4 (4q32.2q35.1)
Pregnancy outcome:
Singleton pregnancy, vaginal 
delivery of female infant at 
gestational week 40
Single embryo transfer
Congenital anomaly:
Coarctation of aorta
Pregnancy outcome:
Vaginal delivery of female 
infant at gestational week 39
Double embryo transfer
Congenital anomaly:
Ureterocele
Pregnancy outcome:
Singleton pregnancy, vaginal 
delivery of male infant at 
gestational week 40
Figure 11 a) Nuclear status and pregnancy outcome of frozen embryo 
transfers leading to congenital anomaly in the Case group (Study III). 
 
b) Pregnancy outcome of frozen embryo transfers leading to congenital 
anomaly in the Control group (Study III). 
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5.4 Pregnancy outcomes of BN and MN embryos: a sub-analysis 
(Study III) 
Pregnancy results of the transferred frozen-thawed embryos including 
exclusively either BN or MN embryos were compared (n = 97 vs. 42, 
respectively) in a sub-analysis. IR was comparable between the subgroups and 
difference in LBR was not different. The number of born infants per transferred 
BN and MN embryos approached but did not meet, statistical significance 
(24.7% vs. 11.9%, p = 0.065). P-value was also calculated for the number of born 
infants per implanted embryos in BN and MN groups, with only a tendency of 
significance (82.7% vs. 50.0% p = 0.056). The miscarriage rate was 30% among 
MN embryos and 17.9% among BN embryos, but the difference was not 
statistically significant (Table 9). 
Table 9. Pregnancy results after transfer of BN or MN frozen-thawed embryos (Study III). 
 
BN  
n (%) 
MN 
n (%) 
p-
valuea OR (95% CI) 
Number of FETs 93 38     
Total number of transferred embryos 97 42     
Implantation rateb 29 (29.9) 10 (23.8) NS 0.73 (0.32 − 1.68) 
Clinical pregnancyc 28 (30.1) 10 (26.3) NS 0.83 (0.36 − 1.93) 
Live birthc 23 (24.7) 5 (13.2) NS 0.46 (0.16 − 1.32) 
No of infantsb 24/97 (24.7) 5/42 (11.9) NS 0.41 (0.15 − 1.16) 
No of infantsd 24/29 (82.7) 5/10 (50.0) NS 4.80 (0.10 − 23.07) 
Miscarriagee 5 (17.9) 3 (30.0) NS 1.97 (0.37 − 10.40) 
Values are numbers (percentages) 
aFisher's exact test, bCalculated per transferred embryo, cCalculated per FET, dCalculated per implanted 
embryo, ePercentage from clinical pregnancies 
Double FETs including both BN and MN embryos were excluded from the analysis 
FET = frozen embryo transfer, BN = binucleated, MN = multinucleated 
5.5 Pregnancy and perinatal outcomes of NC-FET cycles after 
administration of single dose luteal phase triptorelin (Study IV) 
An additional luteal phase triptorelin was given in 65 NC-FET cycles 
(Intervention group); the Control group was comprised of 62 NC-FET cycles 
with standard luteal support (Figure 8). In the Intervention group, LBR was 
30.8%, and the control group was 24.2%, but all differences in pregnancy 
outcomes were statistically insignificant.  
Mean maternal β-hCG concentration measured from ongoing singleton 
pregnancies when the embryo age reached 16 days was lower in the Intervention 
group (n= 18) than in the Control group (n=13) (282.6 ± 179.1 IU/l vs. 416.6 ± 
177.6 IU/I, p= 0.048, respectively). Two single FETs in the Intervention group 
produced twin pregnancies; one resulted in a vanishing twin pregnancy, and the 
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other was a result of simultaneous implantation of frozen-thawed and 
spontaneously fertilized embryos. There was no difference in birth weight of the 
singleton newborns between the groups. Pregnancy and perinatal outcomes are 
presented in Table 8. 
5.6 Pregnancy and perinatal outcomes of AC-FET cycles after 
administration of single dose luteal phase triptorelin (Study V) 
Altogether, 72 AC-FET cycles were enrolled in both the Intervention and the 
Control groups (Figure 8). The rates for implantation, positive pregnancy test, 
and clinical pregnancy were similar between the groups. A difference of 9.8 
percentage points in LBR and 14.7 percentage points in miscarriage rate between 
the Intervention group and the Control group (29.2% vs. 19.4%, and 27.6% and 
42.3%, respectively) were not statistically significant.  
Newborns in the Intervention (n=22) and the Control group (n=15) were healthy, 
and no malformations were detected. Mean birth weights from singleton 
deliveries were comparable between the groups. Pregnancy and perinatal 
outcomes are presented in Table 8.  
The aims and the main results of this thesis are summarized in Table 10.  
Table 10. Aims, study design, and main results of the studies. 
Study 
details Study II Study III Study IV Study V 
Aim of the 
study 
 
 
De novo occurrence of MN after 
embryo freezing and thawing 
 
Association between 
multinucleation, MN sibling 
embryos and clinical factors 
affecting ovarian sensitivity to 
gonadotropin treatment 
Transfer of mononucleated or 
BN/MN frozen-thawed embryo: 
- pregnancy outcomes 
- obstetric and neonatal outcome  
 
Administration of luteal phase single 
dose triptorelin in NC-FET cycles: 
- pregnancy outcomes  
- β-hCG- concentrations at embryo 
age of 16 days 
- Birth weight 
Administration of luteal phase single 
dose triptorelin in AC-FET cycles: 
- pregnancy and neonatal outcomes 
Study 
design 
Retrospective cohort study Retrospective case-control study Prospective randomized clinical pilot 
study 
Prospective interventional pilot study 
Main  
results 
 
 
 
 
 
 
 
 
 
 
The presence of MN embryos prior 
to freezing was not associated with 
formation of MN sibling embryos 
after thawing 
 
Multinucleation associated with 
factors related to good prognosis in 
ART, such as young age and ovarian 
sensitivity to controlled ovarian 
hyperstimulation among women with 
advanced age 
 
The presence of multinucleation was 
similar in embryo cohorts with and 
without cryopreservation 
Frozen–thawed BN and MN 
embryos transferred at the cleavage 
stage had lower than normal 
but still acceptable implantation 
potential and ability to produce 
healthy pregnancies and newborns 
 
Implantation potential of MN 
embryos tended to be lower 
compared to BN embryos 
Live birth rate was 30.8% in the 
intervention group and 24.2%, in the 
control group, but all differences in 
pregnancy outcomes were 
statistically insignificant 
 
β-hCG- concentration was lower in 
the Intervention group 
Live birth rate was 29.2% in the 
intervention group and 19.4% in the 
control group, but all differences in 
pregnancy outcomes were 
statistically insignificant 
 
No difference in neonatal outcome 
was recorded 
ART = assisted reproductive treatment, β-hCG = human chorionic gonadotropin, FET = frozen embryo transfer, BN = binucleated, MN = multinucleated, NC = natural cycle,  
AC = artificial cycle 
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6 DISCUSSION 
6.1 Methodological considerations 
Studying prognostic factors related to FET outcome is challenging, especially 
when ethical and safety aspects are in question. Several study protocols were 
utilized in this thesis, including a case report, a retrospective cohort study, a 
retrospective case-control study, and two prospective interventional studies with 
a crossover design. All these methods have strengths and limitations, which are 
summarized in Table 11. 
Regarding case reports, the endpoint of a single case cannot be generalized, nor 
can conclusions on causal effects be drawn, but case reports enable the 
presentation of novelties and generation of hypotheses for further research 
(Nissen and Wynn, 2014). Cohort studies and case-control studies, two types of 
observational studies, offer the possibility to explore the prevalence of events and 
associations between exposure and endpoints, especially when RCTs are 
ethically questionable. Because subject selection is defined by outcome status, 
case-control studies require a fewer number of subjects compared to cohort 
studies and are suitable for evaluating rare outcomes (Song and Chung, 2010). 
Furthermore, cohorts derived from the unselected patient population illustrate 
real world data. RCTs demonstrate a reference standard for exploration of the 
efficacy of medical interventions but compared to real world data, the study 
population in RCTs is highly selected. Crossover design in prospective studies 
provide a higher number of events in a limited study population and additionally 
increase the homogeneity of the study groups.  
Using the above mentioned study methods, the present study provided novel, 
albeit preliminary, information on de novo multinucleation in embryo cohorts 
after slow freezing and on the clinical significance of blastomere multinucleation 
on pregnancy outcomes after BN/MN FET. Further, this was the first study to 
evaluate the role of triptorelin as adjuvant therapy in NC-FET cycles in a 
prospective setting. Concerning studies involving the evaluation of pregnancy 
outcomes of FET, LBR, and the neonatal outcome was also included. However, 
this study has certain limitations that are discussed below.  
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Table 11. Strengths and limitations. 
Study I 
Merits: 
The first report of conjoined twins after transfer of frozen-thawed MN embryo 
Limitations: 
Case report study of a single case 
Study II         
Merits: 
Data was enrolled from clinical patient sample (representing real world data) 
Embryo screening was performed simultaneously by two experienced observers 
Adjustment was performed for several factors (female age, male age, number of oocytes, 
total and proportional FSH consumption) 
Limitations: 
Retrospective analysis of the data 
Lack of fresh day-3 control group 
Sequential embryo screening 
Results are not directly applicable to vitrification  
Study III 
Merits: 
Data was enrolled from clinical patient sample (representing real world data) 
Embryo screening was perfomed simultaneously by two experienced observers 
Adjustment was performed for several factors (duration of infertility, BMI, degree 
of blastomere survival, resumption of mitosis, number of transferred embryos) 
Detailed and reliable information on the health of the newborns drawn from medical records 
Double FETs of both mononucleated and BN/MN embryos were excluded  
Limitations 
Retrospective analysis of the data 
Low number of Cases and Controls  
Sequential embryo screening 
Cleavage stage of embryos in which bi- or multinucleation was observed was not 
included in the multivariable analysis 
Matching was based only on female age at the time of oocyte retrieval 
Study IV 
Merits: 
Randomized prospective study design 
Strict inclusion criteria 
Logistic regression model was used to exclude carryover effect   
Logistic regression analysis was used for binary variables with generalized estimation  
equation extension to account for dependence among repeated treatments 
Pregnancy outcomes were adjusted for maternal age at COH and duration of infertility 
Limitations: 
Low number of participants  
Lack of placebo  
Drop-out of participants 
Study V 
Merits: 
Prospective interventional study design  
Logistic regression model was used to exclude carryover effect 
Logistic regression analysis was used for binary variables with generalized estimation  
equation extension to account for dependence among repeated treatments 
Pregnancy outcomes were adjusted for several confounding factors (see Figure 10) 
Limitations: 
Low number of participants  
Lack of placebo  
Drop-out of participants after first FET due to cross-over design  
Heterogeneity in developmental age of transferred embryos 
Heterogeneity in the endometrial  preparation methods 
BMI = body mass index, BN = binucleated, COH = controlled ovarian hyperstimulation,  
FET = frozen embryo transfer, FSH = follicle stimulating hormone, MN = mononucleated 
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Study I was the first published case report of CT pregnancy derived from the 
transfer of frozen-thawed MN embryo. Albeit limited in scientific value, this 
documented case inspired us to explore the occurrence of multinucleation in 
frozen-thawed embryos and the relation between nuclear alterations and possible 
complications manifesting later in pregnancy. 
Embryo cohorts in Study II included all consecutive IVF/ICSI cycles during the 
study period, illustrating a cross-section of the IVF/ ICSI cycles performed in the 
public health care IVF Unit of Turku University Hospital without selection bias. 
Although data on the presence of bi- or multinucleation in Studies II and III 
were collected online during ART treatments, analysis of the results was 
performed retrospectively. Some inconsistency in embryo grading records led to 
drop-outs during the data sampling. Several drop-outs also occurred because 
some of the embryos were destroyed when requested by the couple or had 
remained unthawed. Due to the lack of fresh day-3 embryos as controls and the 
natural reduction in multinucleation rate after second and third embryonic 
cleavages, no firm conclusions on the role of cryopreservation on the post-thaw 
occurrence of multinucleation could be made. As for cryopreservation 
techniques, slow freezing was generally used during data collection. More 
recently, a large proportion of IVF clinics have shifted to embryo vitrification. 
Nevertheless, Study II provided novel data on clinical factors associated with 
embryo multinucleation. 
In Studies II and III, embryo evaluation was performed by sequential embryo 
screening, a method used in normal clinical practice. Embryo screening was 
performed simultaneously by two experienced observers to minimize inter-
observer variability. Multinucleation is known to occur with the highest 
frequency after the first embryonic division. The first evaluation of the cleavage 
in sequential screening takes place at day-2 when the normal cleavage stage 
ranges from two to six blastomeres. Therefore, the precise order of mitotic 
divisions by which multinucleation occurred could not be defined. Also, some 
alterations in the nuclear structure may have been underestimated because of the 
transient nature of multinucleation and consequently, some of the embryos 
included in the Control group in Study III may have exhibit multinucleation 
between the screening checkpoints.  
Study III reports the largest number of newborns from BN/MN embryos so far. 
Nevertheless, the study size is still limited. Reliable data on the incidence of CAs 
in newborns conceived from BN/MN FETs require large follow-up studies that 
are not currently available. Thus, our results should be considered preliminary. 
Further, the decision to transfer frozen-thawed BN/MN embryos was based on 
clinical judgment, mainly due to the lack of optional mononucleated embryos. 
However, double FETs of mononucleated and BN or MN embryos were 
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systematically excluded, and only distinctly evaluated BN or MN FETs formed 
the Case group. Moreover, matching was based only on female age at the time of 
oocyte retrieval, and the Control group included a similar number of women as in 
the Case group. In any case, multivariable analysis for confounding factors was 
conducted to minimize bias (Figure 10).  
In our prospective Studies IV and V, a major limitation was the low number of 
participants. Due to limited resources, both studies were designed as pilot studies 
to gain tentative data on the subject. An adequately powered prospective randomi-
zed study with a difference of 9.8 percentage points in LBR, as detected in Study 
V, would have required a sample size of 299 women per group to reach statistical 
significance with 80% power. Further, no placebo was available, and therefore, 
both participants and clinicians were aware of the allocated arm. Strict inclusion 
criteria were set to verify the study’s validity (Table 3). Participants had 
undergone IVF/ICSI for diagnosed female or male infertility and were recruited 
during their clinical visits at the infertility unit without financial compensation. 
Use of donor gametes was an exclusion criterion. Therefore, the study population 
was representative of an ordinary infertility population.  
Study IV was conducted in co-operation with the Väestöliitto Fertility Clinic 
(now Mehiläinen Felicitas) in Turku, and Study V with Tampere University 
Hospital’s Infertility Unit to ensure the target number of participants in the study 
period. For the same reason, a crossover setting was adopted after excluding the 
carryover effect. In both study protocols, a short-acting mid-luteal single dose of 
triptorelin was added to the standard FET protocol. Although no difference in 
clinical outcomes regarding the route of estrogen administration have been 
demonstrated (Glujovsky et al., 2010), use of both transdermal and oral estradiol 
for AC-FET created heterogeneity in the randomization protocol. Furthermore, 
both cleavage stage embryos and blastocysts were transferred. Blastocyst 
cultures would minimize bias caused by embryonic factors, and thus, blastocyst 
transfers would be optimal in studying the effects of different endometrial 
preparation methods, luteal support, and adjuvant therapies.  
As noted above, this study has its limitations. Nevertheless, it provided novel 
data that applies to clinical practice. This study displayed new perspective when 
weighting the significance of embryo multinucleation, and pointed out the need 
for further studies on factors contributing to outcomes of FET, whether related to 
embryos, pharmacological interventions, or patient characteristics. Below, the 
study findings are discussed in detail.  
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6.2 Occurrence of multinucleation in embryo cohorts and embryos 
before freezing and after thawing 
The multinucleation rate was the highest in day-2 embryo cohorts before freezing. 
At least one BN/MN embryo was detected in more than half of the embryo 
cohorts, a finding within the range of previously reported multinucleation rate 
detected both with sequential and continuous embryo screening (Aguilar et al., 
2016, Balakier et al., 2016, Basile et al., 2014, Van Royen et al., 2003). 
Immediately after thawing, de novo multinucleation was seldom detected, and the 
rate of de novo multinucleation was also lower in day-3 frozen-thawed embryo 
cohorts compared to day-2 pre-freeze embryo cohorts. Likewise, the proportion of 
MN embryos to all embryos did not increase in the freezing-thawing process but 
instead showed a slight decline. Even with modern cryotechnology, some embryos 
do not survive freezing and thawing due to injuries of the cell membranes or 
intracellular components. The impact of freezing on nuclear reconstruction should 
become evident after the resumption of mitosis (Guerif et al., 2002). As the decline 
in multinucleation rate from day-2 to day-3 in frozen- thawed embryos and de 
novo multinucleation on day-3 after thawing resembles that described in fresh 
embryo cohorts (Van Royen et al., 2003, Yakin et al., 2005), it may be that slow 
freezing does not cause a major risk for formation of blastomere multinucleation 
during post-thaw mitosis. However, due to the lack of a control group of fresh day-
3 embryo cohort in the present study, a firm conclusion cannot be made. 
Considering the relatively high frequency of the multinucleation among embryos, 
it was of interest to investigate whether multinucleation per se reflects the quality 
of the entire embryo cohort. Embryo eligibility for freezing is coordinated by 
specific selection criteria and therefore, cryopreservation of supernumerary 
embryos can be considered as a sign of the adequate or good quality of embryos 
in a given IVF/ICSI cycle. Although the main focus of the study was on the post-
thaw occurrence of multinucleation, a sub-analysis of IVF/ICSI cycles from year 
2012 allowed comparison of the occurrence of multinucleation in fresh day-2 
embryo cohorts having no suitable embryos for cryopreservation. Multinucleation 
occurred with the same frequency in cycles with and without further 
cryopreservation. Thus, multinucleation of blastomeres was not overrepresented 
in cycles that did not meet the criteria for cryopreservation. Interestingly, the 
presence of MN embryos in good quality embryo cohorts before 
cryopreservation was not associated with the occurrence of multinucleation after 
thawing. In contrast to Meriano et al. (2004), who suggested impaired 
developmental quality of mononucleated sibling embryos, the present study 
supports studies suggesting that multinucleation is an intrinsic feature of an 
embryo rather than a reflection of compromised quality of an entire embryo 
cohort (Egashira et al., 2015, Jackson et al., 1998, Yilmaz et al., 2014). 
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6.3 Factors affecting formation of multinucleation 
Previous studies have evaluated the impact of female age on multinucleation 
independently of other factors affecting ovarian response to COH. In general, no 
association has been found apart from two studies by Moriwaki et al. (2004) and 
Balakier et al. (2016), showing that multinucleation was more common in older 
women. Likewise, the association of multinucleation with findings illustrating 
high response to gonadotropins, such as high estradiol levels, low FSH 
consumption, and an increased number of collected oocytes have been reported 
with conflicting results (Balakier et al., 2016, De Cássia Savio Figueira et al., 
2010, Jackson et al., 1998, Van Royen et al., 2003, Yilmaz et al., 2014). 
The Study II was the first to explore multinucleation and its interaction between 
female age and ovarian response to gonadotropins. In opposite to previous stu-
dies, multinucleation in embryo cohorts before freezing was found to be the most 
frequent among women less than 30 years. In that age category, highly prevalent 
multinucleation rate in embryo cohorts was seen independently of the number of 
harvested oocytes or FSH consumption per collected oocyte. In contrast, in 
women aged over 30 years, the multinucleation rate varied according to the 
number of harvested oocytes and FSH consumption. Ovarian sensitivity to 
gonadotropins seemed to be a risk for blastomere multinucleation in this age 
group. These results add to the evidence that ovarian responsiveness to COH 
associates with the occurrence of multinucleation (De Cássia Savio Figueira et 
al., 2010, Jackson et al., 1998, Van Royen et al., 2003, Yilmaz et al., 2014).  
The number of collected oocytes and the gonadotropin dose during COH in 
normal responders have not been related to increased aneuploidy rate (Sekhon et 
al., 2017). Meiotic errors in oocytes increase with age but interestingly, in this 
study, multinucleation was the most common in the youngest age category, and, 
in the older age categories, multinucleation was associated with a higher 
response to COH. These patient groups show a good prognosis in ART. 
Therefore, findings of the present study could be explained by the hypothesis that 
multinucleation reflects active reparation of abnormal chromosome content 
(Tesarik et al., 1987), especially among women with normal ovarian reserve and 
overall good quality embryo cohort.  
This study provided novel information on the interaction of age and ovarian 
sensitivity to gonadotropins as a modulator of the multinucleation rate. Based on 
this, it can be hypothesized that the origin of blastomere multinucleation can be 
explained, at least partly, by the characteristics of the patient. Further, multi-
nucleation may reflect self-correction events in an embryo.  
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6.4 Pregnancy and obstetric outcomes of BN/MN FETs 
The causes and physiological significance of multinucleation have remained 
unclear. In addition to the most dominant hypothesis for the origin of 
multinucleation, cell cycle and chromosome segregation errors (Hardy et al., 
1993, Munné and Cohen, 1993, Pickering et al., 1995, Winston et al., 1991), 
defective reassembly of nuclear envelope could also be one mechanism leading 
to multinucleation. Also, multinucleation has been postulated to represent a form 
of self-correction mechanism, by which embryo is restoring its viability (Aguilar 
et al., 2016, Balakier et al., 2016, Tesarík et al., 1987). Indeed, few reports of 
healthy newborns from ET or FET of MN embryos have been documented 
(Balakier et al., 2016, Balakier and Cadesky, 1997, Egashira et al., 2015, 
Hashimoto et al., 2015, Jackson et al., 1998, Yilmaz et al., 2014). However, due 
to a limited number of live births, a final conclusion for safety regarding neonatal 
health cannot be drawn. 
In practice, MN embryos are mostly rejected from fresh ET but secondarily used 
for FET if other embryo parameters met the criteria for cryopreservation (Desai 
et al., 2016, Egashira et al., 2015). In this regard, it was natural to choose a 
cohort of BN/MN FETs for our study object. In all parameters evaluating the 
ability to achieve clinical pregnancy, the Control group yielded significantly 
better results. However, in the Case group, an IR of nearly 28%, within the range 
of latest reports from fresh cleavage stage MN ETs, was achieved (Aguilar et al., 
2016, Ergin et al., 2014). In line with the study by Desai et al. (2016) 
investigating LBR of vitrified-warmed blastocysts, the odds for live birth among 
BN/MN frozen-thawed embryos was half of that in Control group. Intriguingly, 
the LBR of 22% observed in the Case group was identical to the LBR of FETs 
reported in National Institute for Health and Welfare records from 2016 in 
Finland (THL, 2018). Thus, although a reduction in pregnancy potential among 
BN/MN embryos was evident, the pregnancy outcome could still be interpreted 
as acceptable.  
Most of the studies report a clear reduction of IR in fresh blastocysts exhibiting 
multinucleation at 2-cell stage (Balakier et al., 2016, Desch et al., 2016, Ergin et 
al., 2014). However, Aguilar et al. (2016) postulated that the implantation 
potential appears to correlate with the developmental stage of the embryo in 
which MN blastomeres are present; that is, reduction in IR seemed to be less 
evident if multinucleation was present only after the first embryonic cleavage. 
Although questioned by Aguilar et al. (2016), an effect on implantation potential 
was  
further reported to be most obvious if, at the 2-cell stage, multinucleation affects 
both blastomeres (Desch et al., 2016). In the present study, multinucleation was 
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detected mostly at the 4-cell or 8-cell stage. Unfortunately, the analyses of the 
pregnancy results according to the developmental stage at the time of 
multinucleation could not be conducted due to a limited number of FET cycles 
and sequential screening of embryos.  
The type of multinucleation pattern has been postulated to relate to different 
chromosomal contents. Meriano et al. (2007) found that fresh MN embryos carry 
a higher number of chromosomal abnormalities compared to BN embryos and 
correspondingly, reported higher IR among BN embryos. Aguilar et al. (2016) 
did not find any relationship between IR and the type of multinucleation detected 
at the 2-cell stage, but interestingly, IR was lower if multinucleation was 
observed at 4-cell stage compared to binucleation. To further explore the subject, 
pregnancy outcomes of frozen-thawed BN and MN embryos were compared in a 
sub-analysis of the present study. However, the number of FETs containing 
exclusively MN embryos remained considerably low, and although the difference 
tended to favor BN FETs, it did not reach statistical significance. Nevertheless, 
such differences in LBR would be clinically relevant, and therefore, further 
studies are warranted. Similarly, statistically insignificant differences in LBR 
(24.7% vs. 13.2%) and miscarriage rate (17.9% vs. 30.0%) in the sub-analysis of 
BN and MN embryos require further studies.  
A tendency to pregnancy loss in MN embryos has earlier been related to short 
cleavage time (Desch et al., 2016). Overall, delayed cleavage during early 
development of MN embryos have been debated to indicate active repair 
mechanisms of the affected blastomeres and therefore, better prognosis. 
Furthermore, if detectable after the 2-cell stage, multinucleation have been linked 
to a more compromised pregnancy outcome (Aguilar et al., 2016, Desai et al., 
2018). In the present study, bi- and multinucleation was detected at a rather late 
cleavage stage. At this stage of embryo development, multinucleation compared 
to binucleation could, therefore, illustrate a more severe form of a 
nuclear/chromosomal abnormality or compromised ability to self-correct, and a 
more pronounced tendency to early pregnancy loss. In light of the reduced 
potential of live birth, cultivation of MN embryos to the blastocyst stage is 
recommended or, secondarily, the transfer of two frozen-thawed MN embryos 
could be justified if mononucleated embryos are not available. 
If not eliminated from the developing blastocyst, the significance of MN 
blastomeres for the viability of pregnancy may depend on whether the BN/MN 
blastomeres are destined to create the inner cell mass or the TE, which later 
forms the placenta. It is unknown whether BN/MN cell lineages in the placenta 
affect placental growth and function and thereby, on obstetrical complications 
(Xanthopoulou et al., 2011). This study closely evaluated the obstetric outcomes 
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of the pregnancies deriving from BN/MN embryos in consideration of possible 
consequences to the pregnancy.  
Study III provided novel data on obstetric outcome, placental weight, and 
neonatal health of pregnancies deriving from frozen- thawed BN/MN embryos 
that had not been evaluated in detail earlier. The results of the study were 
reassuring, while no signs of disturbed trophoblast function or increased obstetric 
complications were detected. In both the Case and the Control groups, full-term 
pregnancies with similar gender distribution were attained, and placental weight 
was comparable between the groups. There was no difference in birth weights of 
the neonates or occurrence of pre-eclampsia or gestational diabetes mellitus, 
obstetric complications related to placental dysfunction and intrauterine growth 
of the fetus. However, detection of obstetric and neonatal problems requires large 
data and results of this study should, therefore, be considered preliminary.  
6.5 Congenital anomalies of neonates conceived from BN/MN FETs 
Neonatal health, including structural deviations of the developing fetus deriving 
from BN or MN embryos, was investigated. CAs are increased in ART 
pregnancies, but the reasons for this increase are obscure. Inspiration to explore 
further the perinatal outcome of MN FET originated from a case of CT after the 
transfer of an 8-cell frozen-thawed embryo exhibiting three MN blastomeres at 
the time of transfer. Thoragopagus twins with two heads, four limbs, and a 
common heart were detected at gestational week 12, and the pregnancy was 
terminated (Study I).  
The prevalence of monozygotic twins is increased after ART compared to natural 
conception, presumably due to in vitro conditions during embryo culture (Aston 
et al., 2008). CT, a complication of monozygotic twins, is an extremely rare 
condition estimated to occur in one per 100,000 to 200,000 spontaneous 
pregnancies (Rees et al., 1993). Among children born after ART treatments, the 
described case of CT was the first in Finland to be reported since the beginning 
of the National Data Collection on infertility treatments (1992-2011) (Mika 
Gissler, personal communication). Remarkably, an identical CT case was 
presented three years later in pregnancy after fresh ET (Serapinas et al., 2016). 
For example, monozygotic twins and also CT are suggested to represent a form 
of blastogenesis defect, which frequently leads to defects in midline formation 
and is typically without genetic origin (Halliday et al., 2010). Considering the 
rarity of the condition, two reported cases of CT after the transfer of an MN 
embryo raises the question: does blastomere multinucleation disturb nuclear and 
68 Discussion  
cellular coordination by exposing the embryo to defective cell migration in the 
inner cell mass and failures during organogenesis? 
Present knowledge on the perinatal outcome of fresh MN ETs is limited to case 
reports and small patient series up to 14 deliveries, including predominantly 
healthy newborns. In addition to the case of CT reported by Serapinas et al. 
(2016), a trisomy 18 and combination of trisomy 21 and 18 after the transfer of 
MN embryo have been documented (Balakier et al., 2016, Balakier and Cadesky, 
1997). Previously, the health of newborns conceived from MN FETs has been 
evaluated only in one study presenting nine healthy babies from the FETs of 
altogether 22 MN embryos (Egashira et al., 2015).  
In this study, the rate for CAs did not differ from that detected in the control 
group, but still, the number of children was too low in both groups to make 
conclusions. Thus, the present study does not give any answer to the question of 
whether there is a causal relationship between multinucleation and CAs. 
Concerns regarding the effect of multinucleation on embryonic development 
have been related to possible deviations in the chromosomal complement, 
affecting the nuclear integrity of the blastomere. The effect of multinucleation on 
the chromosomal constitution would be most likely be seen as segregation errors 
of chromosomes that clinically manifest either as aneuploidy of all blastomeres, 
chromosomal mosaicism, or segmental aneuploidy (Balakier et al., 2016, 
Kligman et al., 1996). However, it is noteworthy that in the Case group of the 
present study, only one neonate with CA had an abnormality in the chromosomal 
constitution that corresponded to segmental aneuploidy. 
Because most authors recommend either to reject MN embryos from transfer or 
to use them as a secondary option (Aguilar et al., 2016, Desch et al., 2016, 
Fauque et al., 2013, Meseguer et al., 2011), adequately powered large scale 
studies on the incidence of CAs among MN embryos remain currently beyond 
the bounds of possible. In light of new evidence that multinucleation may 
represent active repair mechanism to restore euploidy of a mosaic embryo rather 
than to be a definite sign of compromised embryo quality, attitude toward more 
liberal use of MN embryos is taking place. This change in clinical practice 
emphasizes the need for more research on the perinatal consequences of the 
phenomenon. The present study was the first to shed light on the subject 
systematically. The study population is the largest so far to explore the 
occurrence of CAs among neonates born from the transfer of frozen-thawed 
BN/MN embryos, but it is still limited in number. Considering the preliminary 
nature of the results, counseling the couple before the transfer of the BN/MN 
embryos is advisable, and, in the case of ongoing pregnancy, thorough antenatal 
screening is recommended.  
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6.6 Effect of luteal phase GnRH agonist on pregnancy and perinatal 
outcomes 
Study IV was the first prospective randomized study on the effect of short-acting 
luteal phase GnRH agonist on pregnancy outcomes in NC-FET cycles compared 
to standard LPS. The study was planned as a pilot, and, consequently, it was not 
powered enough to show statistical significance. The differences in CPR and 
LBR (11.1 percentage points and 6.6 percentage points, respectively) point to a 
potential benefit of additional luteal phase GnRH agonist and indicate a need for 
larger studies. The effect of luteal phase GnRH agonist substitution in NC-FET 
has previously been evaluated only in one retrospective analysis of different NC-
FET LPS protocols that were used during two consecutive time periods; standard 
LPS was used during the first period and the following period, additional two 
dosages of recombinant hCG and GnRH agonist on day of FET and four days 
later was administered (Orvieto et al., 2016). The ongoing PRs were twice as 
high when the modified LPS protocol was used. It should be questioned whether 
the difference in pregnancy outcomes could be explained by other factors, such 
as a change in laboratory techniques, rather than by the modified FET protocol 
only. 
One possible mechanism in which luteal phase GnRH agonist could affect the 
pregnancy outcomes in NC-FET is the enhanced corpus luteum function and 
therefore, higher levels of endogenous progesterone. As a true agonist, GnRH 
agonist first produces a flare effect, an outburst in gonadotropin secretion, before 
subsequent receptor downregulation. As a consequence, activation of corpus 
luteum function is likely to increase progesterone secretion. Because of its short 
half-live, a single dose of short-acting triptorelin administered during WOI does 
not cause downregulation after a flare. Even if administered daily, suppression of 
gonadotropin secretion would take place only after a few days, when hCG 
production from the implanted embryo would secure the endogenous 
progesterone production.  
A direct effect of GnRH agonist on embryo and embryo-endometrial interaction 
to facilitate implantation has also been proposed. Such an effect could influence 
hCG production by trophoblasts. Tesarik et al. (2006) demonstrated higher levels 
of β-hCG after administration of mid-luteal GnRH agonist. This finding was not 
confirmed by Check et al. (2015) or by the present study. By contrast, in the 
present study, hCG levels were found to be lower among the GnRH receivers 
than in the control group. It has been demonstrated that GnRH and its receptor 
are expressed in human blastocysts (Casañ et al., 1999). 
Furthermore, in vitro experiments as well as in vivo analyses on the relationship 
between GnRH and hCG secretion indicate that GnRH and GnRH agonist indeed 
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induce placental hCG secretion. However, no difference in hCG production was 
recognized in human in vitro model when GnRH agonist was administered in the 
culture media of blastocysts incubated with endometrial cells collected from non-
pregnant uteri during assumed WOI (Klemmt et al., 2009) Taken together, this 
study is in line with data suggesting that a single dose of GnRH agonist 
administered during WOI does not have such an effect on embryo that would 
subsequently modulate trophoblast function and increase hCG secretion. 
However, the absolute hCG level does not as such reflect trophoblast function, 
for example, their invasiveness (Alfthan et al., 1993, Fritz and Speroff, 2005). 
Thus, no conclusion can be made on the hypothetical effect of GnRHa on 
embryos, trophoectoderm, and trophoblasts. 
Study V was the first to report live birth and perinatal outcomes after luteal 
phase single dose GnRH agonist in AC-FET cycles. Like Study IV, this study 
was a pilot study and lacked the power to show statistical significance for the 9.8 
percentage points difference in LBR favoring intervention. Due to the lack of 
corpus luteum in AC-FET, the positive effect of luteal phase GnRH agonist 
administered during WOI would be transmitted solely through a direct effect on 
the embryo or the endometrium. In hormonally substituted cycles of oocyte 
recipients, GnRH agonist in the luteal phase increased both IR and LBR in a 
prospective RCT by Tesarik et al. (2004). However, no difference in IR, CPR, or 
ongoing PR was detected in the prospective randomized trials on GnRH support 
in AC-FET (Davar et al., 2015; Ye et al., 2019). One explanation for these 
discrepancies may be due to the lack of power, but different immunological 
adaptations to invading trophoblasts and the possible modulatory effect of GnRH 
agonist may explain the difference in pregnancy outcomes between oocyte 
recipients and women utilizing autologous oocytes (Savasi et al., 2016).  
Interestingly, the difference in LBR in this study was based on a higher number 
of miscarriages in the group receiving standard LPS. Previously, few studies 
have documented early pregnancy wastage to be more prominent in AC-FET 
cycles compared to NC- or OI-FET cycles (Hatoum et al., 2018, Jouan et al., 
2016, Tomás et al., 2012). Whether the GnRH agonist at the time of implantation 
in AC-FETs could modulate endometrial receptivity and decrease the tendency to 
early pregnancy loss merits further attention. 
In Studies IV and V, the birth weight of the newborns was recorded. In both 
studies, no statistical differences in birth weights of newborns from singleton 
deliveries were detected, although in Study IV newborns from the Intervention 
group weighed 300g less than in the Control group. In Study V, the occurrence 
of CAs was documented, and no congenital anomalies were detected after 
administration of luteal phase GnRH agonist. These preliminary results on the 
health of newborns are the first reported after mid-luteal administration of GnRH 
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agonist in NC- or AC-FET. According to the available data, the utilization of 
GnRH  
agonist during pregnancy seems safe (Abu-Heija et al., 1995, Cahill et al., 1994, 
Chardonnens et al., 1998, Gartner et al., 1997, Marcus and Ledger, 2001). 
However, before implementing adjuvant therapy into standard ART protocol, the 
neonatal outcome should be comprehensively evaluated in larger, adequately 
powered studies.  
6.7 Future aspects 
As shown in the present study, MN embryos are relatively common in embryo 
cohorts subjected to slow freezing. The presence of MN embryos in an embryo 
cohort before freezing was not associated with de novo multinucleation rate after 
thawing. In line with the previously reported decline in multinucleation rate in 
fresh embryos from day-2 to day-3 of culture, multinucleation rate was higher in 
day-2 embryos than in day-3 embryos, after thawing and overnight culture. 
However, to verify any influence of cryopreservation on multinucleation, further 
studies with fresh embryos as controls are warranted.  
The present study was carried out using the slow freezing technique, which was 
widely utilized at the time of data collection. Since then, the cryopreservation 
techniques have shifted toward vitrification. Therefore, studies comparing 
multinucleation in frozen-thawed and vitrified-warmed cleavage stage embryos 
would bring new information on the safety of these cryopreservation methods, 
especially regarding nuclear dynamics.  
The clinical relevance of blastomere multinucleation is yet to be determined. A 
particularly intriguing question is whether blastomere multinucleation is a 
consequence rather than a cause of aneuploidy, as suggested by Tesarik (2018) in 
his comment to Study III. Therefore, further studies are needed to clarify 
whether multinucleation demonstrates a physiological repair mechanism during 
early embryonic development, which is, however, challenging as the origin of 
multinucleation is probably multifactorial. For example, the hypothesis that 
defective reassembly of the nuclear envelope may be one mechanism leading to 
multinucleation needs to be tested.  
Prognostic value of multinucleation for FET outcomes is not thoroughly 
clarified. Larger studies are needed to detect whether the significance of 
blastomere multinucleation after the first mitotic cleavage differs from that after 
the second or third cleavage. Continuous embryo monitoring should be the 
preferred evaluation method due to the transient nature of the phenomenon. 
Further, the inclusion of only blastocyst stage embryos into the analysis of 
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pregnancy outcomes would reduce bias caused by heterogeneity in the 
developmental potential of cleavage stage embryos. Also, further effort should 
focus on potential differences in clinical outcomes between BN and MN FET. In 
all, follow-up studies with larger sample sizes are necessary to verify the impact 
of blastomere multinucleation on pregnancy, obstetric, and neonatal outcomes.  
The literature on the efficacy of mid-luteal GnRH agonist as adjuvant therapy in 
fresh IVF/ICSI cycles is conflicted. In FET cycles, only limited preliminary data 
are available, indicating a possible beneficial effect of luteal phase GnRH agonist 
in FET cycles. However, adequately powered large multicenter randomized 
prospective studies are warranted to evaluate the effect of mid-luteal phase 
GnRH agonist adjuvant therapy in clinical use, both in NC- and AC-FET cycles. 
In addition to single dose administration, exploration of the effect of repeated 
dosages would also be of interest. Future research on the mechanisms behind 
GnRH action in the luteal phase is awaited. Furthermore, the obstetric and neo-
natal outcomes should always be included as outcomes in future studies to obtain 
data on the safety of modified ART treatments. 
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7 CONCLUSIONS 
The main conclusions were as follows: 
1. Multinucleation is commonly seen in embryos and good quality day-2 
embryo cohorts before freezing, but de novo multinucleation is less likely 
to occur in day-3 frozen-thawed embryo cohorts. The presence of BN/MN 
embryos in day-2 fresh embryo cohorts does not illustrate the propensity 
of sibling embryos to develop multinucleation after freezing and thawing. 
2. Multinucleation is highly prevalent in fresh day-2 embryo cohorts in 
women less than 30 years old, regardless of ovarian response during COH. 
In older women, the occurrence of multinucleation is associated with 
ovarian sensitivity to COH, and this association is sustained in frozen-
thawed embryos. Thus, female characteristics and conditions during COH 
are possibly more probable contributors to occurrence of multinucleation 
than slow freezing process. 
3. Pregnancy potential of frozen-thawed BN/MN embryos is compromised 
compared to mononucleated embryos, but nevertheless, acceptable CPR 
and LBR are achieved. Compared to BN embryos, MN embryos may be 
more prone to early pregnancy loss in FET cycles. According to the 
preliminary data, the risk for obstetric complications or fetal 
malformations is similar in pregnancies deriving from mononucleated and 
BN/MN embryos. The present results speak against the policy of 
discarding BN/MN embryos from cryopreservation and transfer.  
4. CPR and LBR in NC-FET cycles and CPR in AC-FET tended to be higher 
when a single dose of triptorelin was given during WOI as an adjuvant to 
standard luteal support. As the prospective studies were designed as pilots, 
they were underpowered to show statistical significance. As such, the 
results imply a need for larger multicenter studies. 
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